<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001115" GROUP_ID="AIRWAYS" ID="781799100408502306" MERGED_FROM="" MODIFIED="2011-03-11 20:06:53 +0100" MODIFIED_BY="Emma Welsh" NOTES="&lt;p&gt;Exported from Review Manager 4.2.1&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Imported 22_2_3&lt;br&gt; [BR] Wow, that long ago? Surely you jest!&lt;/p&gt;&lt;p&gt;Technical editing by CJC 25_2_3&lt;br&gt; [BR] Thanks, signed lazy boy!&lt;/p&gt;&lt;p&gt;Authors' Contribution: fine&lt;br&gt;[BR] No change.&lt;/p&gt;&lt;p&gt;Objectives: fine (would efficacy be more accurate than effect - i do not have very strong feelings on this)&lt;br&gt;[BR] Changed to efficacy as often as necessary throughout the text.&lt;/p&gt;&lt;p&gt;References: I have copied the Rudnitsky citation into the other reference field for 1993a. I assume it is the same trial. Did you want to cite current versions of the two Cochrane reviews? (Mine and Brian's)?&lt;br&gt;[BR] Done.&lt;/p&gt;&lt;p&gt;Table of included studies: excellent&lt;br&gt;[BR] Merci buckets - that's Canadian for: &amp;quot;Thanks, I needed that!&amp;quot;.&lt;/p&gt;&lt;p&gt;Metaview Labels: Look good. As far as I can see the trials that have data entered for separate patient groups are not counting the same patients twice, so no problems here.&lt;br&gt;[BR] No change.&lt;/p&gt;&lt;p&gt;Synopsis: good&lt;br&gt;[BR] No change.&lt;/p&gt;&lt;p&gt;Abstract: date of search to be added here please. Otherwise fine and results all match metaview.&lt;br&gt;[BR] Date added (June 2003).&lt;/p&gt;&lt;p&gt;Background: &amp;quot;To date, only a limited number of trials have examined continuous versus intermittent nebulisation and they have yielded inconsistent results. We are aware of one published systematic review on the role of continuous versus intermittent nebulisation in the treatment of acute asthma in the ED (Rodrigo 2002); however, this review had several flaws.&amp;quot; &lt;br&gt;**** Would you like to summarise the main problems with the Rodrigo review?&lt;br&gt;[BR] Change to: ....ED (Rodrigo 2002); however, our review includes other recent primary publications, uses Cochrane methods and was designed to further clarify the role of CBA in acute asthma.&lt;/p&gt;&lt;p&gt;Methods: fine&lt;br&gt;[BR] No change.&lt;/p&gt;&lt;p&gt;Results: &amp;quot;Sufficient information was available to examine the time course for the changes observed at the end of the trial period reported above. In the first 60 minutes, differences between CBA and intermittent treatment were not obvious in PEFR (SMD: 0.14; 95% CI: -0.05 to 0.3) and were small when FEV-1 was reported (SMD: 0.30; 95% CI: 0.05 to 0.5). &amp;quot; I have changed a typo in the CI for FEV1 here to match metaview.&lt;br&gt;[BR] No change; thanks.&lt;/p&gt;&lt;p&gt;&amp;quot;There was no difference in hospitalisation for the studies where participants had mild-moderate asthma (RR: 1.12; 95% CI: 0.4 to 2.9). A difference in hospital admission rates was identified for patients for the severe asthma subgroup treated with CBA (RR: 0.64; 95% CI: 0.5 to 0.9). This pooled result did not demonstrate significant heterogeneity (chi square = 2.95; df = 4; p = 0.56).&amp;quot;&lt;/p&gt;&lt;p&gt;I am afraid I have a major problem with this! Please see the article by Altman in the BMJ http://bmj.com/cgi/content/full/326/7382/219 about this. You must compare the groups with each other not with the placebo individually and when you do it is most unlikely that they are significantly different. This needs to be re-written much more cautiously in my view. The mild group may well be underpowered to show a difference as the admission rates are lower........ I think that it is reasonable to conclude that CBA has advantages in the more severe patients but would retain an open mind about the less severe ones, lest you fall into the same trap as the Rodrigo review!&lt;br&gt;[BR] I did the calculations and the interaction terms were NOT statistically different (based on the Altman approach, the p = 0.76!).&lt;/p&gt;&lt;p&gt;Have re-written the section as follows: &amp;quot;There was no apparent difference in hospitalisation for the studies where participants had mild-moderate asthma (RR: 1.12; 95% CI: 0.4 to 2.9); however, the confidence intervals are wide and the sample is small. Patients with severe asthma had fewer hospital admissions when treated with CBA (RR: 0.64; 95% CI: 0.5 to 0.9). This pooled result did not demonstrate significant heterogeneity (chi square = 2.95; df = 4; p = 0.56).&amp;quot;&lt;/p&gt;&lt;p&gt;While the CBA delivery was well tolerated, the efficacy in patients with severe asthma, its possible expense compared to other therapies and its more complex nature argues against its indiscriminate use in the emergency department treatment of acute asthma. &lt;/p&gt;&lt;p&gt;Discussion: good (except as above re sub-groups).&lt;br&gt;[BR] No other changes.&lt;/p&gt;&lt;p&gt;Conclusions: do you really need all the proposed research. Does it matter which is used in the end....?&lt;br&gt;[BR] I have deleted one section; however, we felt there was room for more research in this area.&lt;/p&gt;&lt;p&gt;Contentious issues: was the division into severe and less severe subgroups pre-specified in the protocol? How did you make the cut between the two groups? Was the definition independent of the outcome being measured (to avoid regression to the mean)?&lt;br&gt;[BR] It was defined a priori, is the same division we used in MgSO4 and we have adopted ever since. It seems to have face validity and Paul approved of it.&lt;/p&gt;&lt;p&gt;Spellchecked: not yet&lt;br&gt;[BR] Done 28/07/2003 BHR.&lt;/p&gt;&lt;p&gt;Next action: Back to Toby for authors response to the subgroups issue please.&lt;br&gt;[BR] Back atcha.&lt;/p&gt;&lt;p&gt;This is a high quality review!&lt;br&gt;[BR] Thanks.&lt;br&gt;_____________________________________________________________________&lt;br&gt;Brian,&lt;br&gt;It is a pleasure to edit your reviews as you make all the changes very easy to see. I have merely altered the additional discussion sentence above to read better!&lt;br&gt;&amp;quot;While the CBA delivery was well tolerated, with good efficacy in patients with severe asthma, its possible expense compared to other therapies and its more complex nature argues against its indiscriminate use in the emergency department treatment of acute asthma.&amp;quot;&lt;br&gt;This can now go out for peer review.&lt;br&gt;Cheers,&lt;br&gt;Chris.&lt;br&gt;_______________________&lt;br&gt;Peer reviewer comments are very positive. Typo in number of patients changed at the beginning of the results section.&lt;br&gt;&amp;quot;a total of 461 patients have been studied (229 with CBA; 232 with intermittent beta-agonists). &amp;quot;&lt;/p&gt;&lt;p&gt;The only substantial point raised is whether there is sufficient data to support the statement that CBA treatment &amp;quot;appears to be safe and well tolerated&amp;quot;. In my view this is already a cautious statement so I am happy for this to go for publication unchanged except for the typo above. I have run spell check on this review.&lt;/p&gt;&lt;p&gt;CJC&lt;br&gt;Old title: =Continuous versus intermittent beta-agonists in the treatment of acute asthma&lt;/p&gt;" NOTES_MODIFIED="2011-03-09 16:47:12 +0000" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="CIBA-AST" REVMAN_SUB_VERSION="5.0.25" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2011-03-11 20:06:53 +0100" MODIFIED_BY="Emma Welsh">
<TITLE>Continuous versus intermittent beta-agonists for acute asthma</TITLE>
<CONTACT MODIFIED="2011-03-11 20:06:53 +0100" MODIFIED_BY="Emma Welsh"><PERSON ID="55887BAA82E26AA20178986BA5476D18" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Carlos</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Camargo Jr</LAST_NAME><POSITION>Director</POSITION><EMAIL_1>ccamargo@partners.org</EMAIL_1><URL>www.emnet-usa.org</URL><ADDRESS><DEPARTMENT>Department of Emergency Medicine</DEPARTMENT><ORGANISATION>Massachusetts General Hospital</ORGANISATION><ADDRESS_1>326 Cambridge St, Suite 410</ADDRESS_1><CITY>Boston</CITY><ZIP>02114</ZIP><REGION>Massachusetts</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+001 617 726 5276</PHONE_1><FAX_1>+001 617 724 4050</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2011-03-11 20:06:53 +0100" MODIFIED_BY="Emma Welsh"><PERSON ID="55887BAA82E26AA20178986BA5476D18" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Carlos</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Camargo Jr</LAST_NAME><POSITION>Director</POSITION><EMAIL_1>ccamargo@partners.org</EMAIL_1><URL>www.emnet-usa.org</URL><ADDRESS><DEPARTMENT>Department of Emergency Medicine</DEPARTMENT><ORGANISATION>Massachusetts General Hospital</ORGANISATION><ADDRESS_1>326 Cambridge St, Suite 410</ADDRESS_1><CITY>Boston</CITY><ZIP>02114</ZIP><REGION>Massachusetts</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+001 617 726 5276</PHONE_1><FAX_1>+001 617 724 4050</FAX_1></ADDRESS></PERSON><PERSON ID="5452" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Carol</FIRST_NAME><LAST_NAME>Spooner</LAST_NAME><POSITION>Research Associate</POSITION><EMAIL_1>cspooner@ualberta.ca</EMAIL_1><ADDRESS><DEPARTMENT>Division of Emergency Medicine</DEPARTMENT><ORGANISATION>1G1.52 Walter Mackenzie Health Centre</ORGANISATION><ADDRESS_1>8440 - 112 ST</ADDRESS_1><CITY>Edmonton</CITY><ZIP>T6G 2B7</ZIP><REGION>Alberta</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 780 407-7576</PHONE_1><FAX_1>+1 780 407-3314</FAX_1></ADDRESS></PERSON><PERSON ID="FB72D3DD82E26AA20100F9CCFABFA64F" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Brian</FIRST_NAME><MIDDLE_INITIALS>H</MIDDLE_INITIALS><LAST_NAME>Rowe</LAST_NAME><SUFFIX>MD, MSc, CCFP (EM), FCCP (BR)</SUFFIX><POSITION>Professor and Research Director</POSITION><EMAIL_1>brian.rowe@ualberta.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Emergency Medicine</DEPARTMENT><ORGANISATION>University of Alberta</ORGANISATION><ADDRESS_1>Room 1G1.43 Walter C. Mackenzie Health Sciences Centre</ADDRESS_1><ADDRESS_2>8440  112th Street</ADDRESS_2><CITY>Edmonton</CITY><ZIP>T6G 2B7</ZIP><REGION>Alberta</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 780 407 6707</PHONE_1><PHONE_2>+1 780 407 6761</PHONE_2><FAX_1>+1 780 407 3982</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2011-03-09 11:22:39 +0000" MODIFIED_BY="Emma J Welsh">
<UP_TO_DATE>
<DATE DAY="18" MONTH="2" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="18" MONTH="2" YEAR="2011"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="8" MONTH="2" YEAR="2012"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2003"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2003"/>
</DATES>
<WHATS_NEW MODIFIED="2011-03-09 11:27:45 +0000" MODIFIED_BY="Emma J Welsh">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-03-09 11:27:45 +0000" MODIFIED_BY="Emma J Welsh">
<DATE DAY="9" MONTH="3" YEAR="2011"/>
<DESCRIPTION>
<P>New literature search run. One abstract added to 'studies awaiting classification' (<LINK REF="STD-Rose-2010" TYPE="STUDY">Rose 2010</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2011-03-09 11:23:07 +0000" MODIFIED_BY="Emma J Welsh">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-03-09 11:23:07 +0000" MODIFIED_BY="Emma J Welsh">
<DATE DAY="21" MONTH="5" YEAR="2009"/>
<DESCRIPTION>
<P>Change of contact details for primary author</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-05-21 11:06:17 +0100" MODIFIED_BY="Toby J Lasserson">
<DATE DAY="17" MONTH="2" YEAR="2009"/>
<DESCRIPTION>
<P>Literature search run: no new studies identified. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-02-17 08:09:35 +0000" MODIFIED_BY="Toby J Lasserson">
<DATE DAY="23" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="1" MONTH="8" YEAR="2003"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Division of Emergency Medicine, University of Alberta, Edmonton</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>National Institute of Health (CAC; NIH HL - 03533), Bethesda</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Canada Institute of Health Research (BHR), Ottawa</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Garfield Weston Foundation</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-03-09 16:47:12 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-07-23 09:44:58 +0100" MODIFIED_BY="Toby J Lasserson">
<TITLE MODIFIED="2008-07-23 09:44:58 +0100" MODIFIED_BY="Toby J Lasserson">Continuous versus intermittent beta-agonists for acute asthma</TITLE>
<SUMMARY_BODY>
<P>During acute asthma attacks, inhaled beta-agonists (reliever medications) are used to treat spasm in the airways in the lungs. The medication can be administered by wet nebulisation or from an inhaler with a holding chamber; wet nebulisation may be delivered in a continuous or intermittent fashion. This review has collected information from randomised controlled trials comparing continuous to intermittent nebulised delivery methods in acute asthma attacks. Overall, differences were found between the two methods, with continuous nebulisers producing a modest reduction in admissions compared to intermittent beta-agonist therapy. This finding was especially pronounced in severe acute asthma. Continuous nebuliser therapy may be more effective than intermittent nebulisers for delivering beta-agonist drugs to relieve airway spasm in selected asthma populations.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-03-09 11:28:06 +0000" MODIFIED_BY="Emma J Welsh">
<ABS_BACKGROUND>
<P>Patients with acute asthma treated in the emergency department are frequently treated with intermittent inhaled beta-agonists delivered by nebulisation. The use of continuous beta-agonist (CBA) via nebulisation in the emergency setting may offer additional benefits in acute asthma.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the efficacy (e.g., reductions in admission, improvement in pulmonary functions) and risks (e.g., adverse events, effects on vital signs) of continuous versus intermittent inhaled beta-agonists for the treatment of patients with acute asthma managed in the emergency department.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2011-03-09 11:28:06 +0000" MODIFIED_BY="Emma J Welsh">
<P>Randomised controlled trials were identified from the Cochrane Airways Group Specialised Register of trials. In addition, primary authors and content experts were contacted to identify eligible studies. Bibliographies from included studies, known reviews and texts were also searched. The search is considered updated to February 2011.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Only randomised controlled trials (RCTs) were eligible for inclusion. Studies were included if patients presented with acute asthma and were treated with either continuous or intermittent inhaled beta-agonists early in the ED treatment. "Continuous" nebulisation was defined as truly continuous aerosol delivery of beta-agonist medication (e.g., using a commercially available large-volume nebuliser, or a small-volume nebuliser with infusion pump) or sufficiently frequent nebulisations that medication delivery was effectively continuous (i.e., 1 nebulisation every 15 minutes or &gt; 4 nebulisations per hour). Studies also needed to report either pulmonary function or admission results. Two reviewers independently selected potentially relevant articles and two additional reviewers independently selected articles for inclusion. Methodological quality was independently assessed by two reviewers.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Data were extracted independently by two reviewers if the authors were unable to verify the validity of information. Missing data were obtained from authors or calculated from other data presented in the paper. The data were analysed using the Cochrane Review Manager (Version 4.1). Relative risks (RR), weighted mean differences (WMD) and standardized mean differences (SMD) are reported with corresponding 95% confidence intervals (CI); both peak expiratory flow rates (PEFR) and forced expiratory volume in one second (FEV-1) data are reported. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>165 trials were reviewed and eight were included; a total of 461 patients have been studied (229 with CBA; 232 with intermittent beta-agonists). Overall, admission to hospital was reduced with CBA compared to intermittent beta-agonists (RR: 0.68; 95% CI: 0.5 to 0.9); patients with severe airway obstruction at presentation appeared to benefit most from this intervention (RR: 0.64; 95% CI: 0.5 to 0.9). Patients receiving CBA demonstrated small but statistically significant improvements in pulmonary function tests when all studies were pooled. Patients receiving CBA had greater improvements in % predicted FEV-1 (SMD: 0.3; 95% CI: 0.03 to 0.5) and PEFR (SMD: 0.33; 95% CI: 0.1 to 0.5); this effect was observed by 2-3 hours. Continuous treatment was generally well tolerated, with no clinically important differences observed in pulse rate (WMD: -2.87; 95% CI: -6.0 to 0.3) or blood pressure (WMD: -1.75; 95% CI: -5.6 to 2.1) between the treatment groups. Tremor was equally common in both groups (OR: 0.81; 95% CI: 0.5 to 1.3) and potassium concentration was unchanged (WMD: 0.02; 95% CI: -0.2 to 0.2). </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Current evidence supports the use of CBA in patients with severe acute asthma who present to the emergency department to increase their pulmonary functions and reduce hospitalisation. Moreover, CBA treatment appears to be safe and well tolerated in patients who receive it. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-03-09 16:47:12 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND>
<P>Acute asthma is a common presenting complaint to the emergency department (ED). In the United States, acute asthma accounts for approximately 2 million ED visits per year (<LINK REF="REF-Mannino-1998" TYPE="REFERENCE">Mannino 1998</LINK>). Approximately 20-30% of these patients will require admission to the hospital; of those discharged from the ED after apparently successful treatment, approximately 10-20% will relapse within two weeks (<LINK REF="REF-Camargo-1998" TYPE="REFERENCE">Camargo 1998</LINK>). The cost of asthma care is enormous, and care of the acute episode (e.g., emergency department and hospitalizations) represents approximately 25% of all care for this problem (<LINK REF="REF-Weiss-2001" TYPE="REFERENCE">Weiss 2001</LINK>).<BR/> <BR/>The enormity of asthma as a health care problem worldwide has led to the creation of several national (<LINK REF="REF-Boulet-1999" TYPE="REFERENCE">Boulet 1999</LINK>; <LINK REF="REF-NAEPP-1997" TYPE="REFERENCE">NAEPP 1997</LINK>; <LINK REF="REF-BTS-1997" TYPE="REFERENCE">BTS 1997</LINK>) and international (<LINK REF="REF-GINA-2002" TYPE="REFERENCE">GINA 2002</LINK>) asthma guidelines. These guidelines generally include sections that focus care in the acute setting. There is general agreement that beta-agonists, such as albuterol (salbutamol), and corticosteroids, such as prednisone, are first-line agents for acute asthma. Beta-agonists are used to provide rapid symptom relief, whereas corticosteroids are used to counter airway inflammation and hasten resolution of the asthma exacerbation. Although both agents are widely used in the acute setting, there remain numerous controversies regarding the appropriate dose, frequency, and route of beta-agonist delivery. </P>
<P>With regard to beta-agonists, most experts (<LINK REF="REF-NAEPP-1997" TYPE="REFERENCE">NAEPP 1997</LINK>; <LINK REF="REF-Boulet-1999" TYPE="REFERENCE">Boulet 1999</LINK>) suggest that the inhaled route is superior to parenteral routes; this assertion is the focus of another systematic review by the members of the Cochrane Airways Group (<LINK REF="REF-Travers-2001" TYPE="REFERENCE">Travers 2001</LINK>). Even among those who contend that inhaled therapy is superior, there are controversies concerning the route of inhaled beta-agonist delivery. A recent systematic review found no material difference in the clinical efficacy of metered-dose inhalers (MDIs) with holding chambers versus wet nebulisers in acute asthma (<LINK REF="REF-Cates-2006" TYPE="REFERENCE">Cates 2006</LINK>). Current recommendations suggest that either MDI or nebulisation may be used in acute asthma.</P>
<P>The focus of the present review is the assertion that "continuous" inhaled beta-agonist therapy is more efficacious for acute asthma than the conventional (intermittent) method of beta-agonist delivery (e.g., 2.5 mg albuterol nebulisations every 20-30 minutes, or &lt; or = to 3 nebulisations per hour). Given current practice patterns, the most important comparison is between continuous nebulisation and intermittent nebulisation. Continuous nebulisation may be delivered using commercially-available machines or through nebulisation systems devised locally (e.g., using an infusion pump). Potential advantages of continuous nebulisation include reduced time and labor costs (by obviating multiple refills of the nebuliser) and more consistent medication delivery; the latter feature may allow deeper penetration into the patient's airways and greater reduction of bronchoconstriction. Moreover, continuous nebulisation may result in fewer side effects due to consistent (rather than bolus) beta-agonist delivery. </P>
<P>To date, only a limited number of trials have examined continuous versus intermittent nebulisation and they have yielded inconsistent results. We are aware of one published systematic review on the role of continuous versus intermittent nebulisation in the treatment of acute asthma in the ED (<LINK REF="REF-Rodrigo-2002" TYPE="REFERENCE">Rodrigo 2002</LINK>); however, our review includes other recent primary publications, uses Cochrane methods and was designed to further clarify the role of CBA in acute asthma.</P>
</BACKGROUND>
<OBJECTIVES>
<P>The objective of this review was to determine the effect (on pulmonary function, admission, and other outcomes) of treatment with continuous versus intermittent inhaled beta-agonist therapy in the first two hours of ED treatment for acute asthma.</P>
<P>Specific Aims: To quantify the effect of continuous inhaled beta-agonist therapy compared to the effect of these agents given intermittently. The specific outcomes included the effect of different beta-agonist delivery techniques on: (1) pulmonary function (e.g., peak expiratory flow rate [PEFR] and forced expiratory volume in 1 second [FEV-1]) (2) admission (e.g., time to decision, % admission). (3) other clinical outcomes (e.g., vital signs, symptom scores, adverse effects). (4) economic endpoints.</P>
</OBJECTIVES>
<METHODS MODIFIED="2011-03-09 16:44:29 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2011-03-09 11:30:03 +0000" MODIFIED_BY="Emma J Welsh">
<CRIT_STUDIES>
<P>To be considered, reported studies had to be randomised controlled clinical trials (RCT). We accepted blinded and unblinded trials, but not cohort or pseudo-randomised trials.<BR/> </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Studies including only patients presenting to an ED or its equivalent were considered for inclusion in the review. If patients from other settings could be removed easily from the study (for example if stratified randomisation was employed) these data were also considered. Studies recruiting either children or adult patients were reviewed and patient age formed one of the subgroup analyses. </P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Patients in studies had to be randomised to receive either continuous or intermittent inhaled beta-agonists early in the ED treatment. "Continuous" nebulisation was defined as truly continuous aerosol delivery of beta-agonist medication (e.g., using a commercially available large-volume nebuliser, or a small-volume nebuliser with infusion pump) or sufficiently frequent nebulisations that medication delivery was effectively continuous (i.e., 1 nebulisation every 15 minutes or &gt; 4 nebulisations per hour). Since acute asthmatics require additional treatments (e.g., corticosteroids, ipratropium bromide, magnesium sulfate, etc.) data for any co-interventions were recorded or requested from the authors when not reported in the studies.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2011-03-09 11:30:03 +0000" MODIFIED_BY="Emma J Welsh">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-07-23 09:45:37 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Change in pulmonary function</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2011-03-09 11:30:03 +0000" MODIFIED_BY="Emma J Welsh">
<OL>
<LI>Admission to the hospital or discharge from ED</LI>
<LI>Other clinical outcomes (e.g., vital signs, symptom scores)</LI>
<LI>Adverse effects (e.g., tremor, nausea, etc).</LI>
<LI>We searched for results from economic analyses; however, few were identified.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-03-09 16:44:29 +0000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2011-03-09 16:44:29 +0000" MODIFIED_BY="[Empty name]">
<P>Trials were identified using the Cochrane Airways Group Specialised Register of trials, which is derived from systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED and PsycINFO, and handsearching of respiratory journals and meeting abstracts (please see the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/AIRWAYS/frame.html">Airways Group Module</A> for further details). The Register contains a variety of studies published in foreign languages, and we did not exclude trials on the basis of language. All records in the Specialised Register coded as 'asthma' were searched using the following terms:</P>
<P>(emerg* or acute or status or sever* or emerg* or exacerbat*) AND ("beta* agonist*" or bronchodilat* or albuterol or salbutamol or ventolin or proventil or metaproterenol or alupent or terbutaline or bricanyl or isoproterenol or epinephrine or adrenaline or isoprenaline or hexoprenaline or reproterol or broxaterol or carbuterol or fenoterol or formeterol or pirbuterol or rimiterol or salmeterol or tolubuterol or *terol)</P>
<P>The most recent serach was conducted in February 2011.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2011-03-09 11:30:16 +0000" MODIFIED_BY="Emma J Welsh">
<P>Additional efforts to locate potential trials were as follows:</P>
<OL>
<LI>Reference lists of all available primary studies and review articles were reviewed to identify potentially relevant citations.</LI>
<LI>Inquiries were made regarding other published or unpublished trials known or supported by the authors of the primary studies so that these results could be included in this review.</LI>
<LI>The scientific advisors of the various pharmaceutical companies that manufacture aerosol delivery devices were contacted for any unpublished or interim results on relevant research.</LI>
<LI>Search of CENTRAL was completed using the following terms: asthma AND continuous AND (albuterol OR salbutamol OR ventolin OR proventil OR metaproterenol OR alupent OR terbutaline OR bricanyl).</LI>
<LI>Finally, personal contact with colleagues, collaborators and other trialists working in the field of asthma was made to identify potentially relevant studies.</LI>
</OL>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-03-09 11:29:35 +0000" MODIFIED_BY="Emma J Welsh">
<STUDY_SELECTION MODIFIED="2008-07-23 09:47:34 +0100" MODIFIED_BY="Toby J Lasserson">
<P>From the title, abstract, or descriptors, two reviewers (CAC, BHR) independently reviewed literature searches to identify potentially relevant trials for full review. Searches of bibliographies and texts were conducted to identify additional studies. From the full text, using specific criteria, two reviewers (CAC, BHR) independently selected trials for inclusion in this review. Inter-rater reliability was measured by using simple agreement and kappa statistics. Disagreement was resolved by consensus or third party adjudication (CHS).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-07-23 09:47:56 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Data for the trials were extracted by two reviewers (CAC, BHR) and entered into the Cochrane Collaboration software program (Review Manager). Primary study authors were requested to confirm data extraction and provide additional clarification and information for the review whenever there was a need. In some cases, expansion of graphic representations of data from the manuscripts were used to estimate missing data. All data, numeric calculations and graphic extrapolations were independently confirmed (CHS).</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2008-07-23 09:47:43 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Methodological quality assessment was performed by two reviewers working independently (CAC, BHR). Inter-rater reliability was measured by using simple agreement and kappa statistics. Both reviewers used two approaches to grade quality:</P>
<P>1. Allocation concealment. Using the Cochrane (<LINK REF="REF-Shultz-1995" TYPE="REFERENCE">Shultz 1995</LINK>) approach to assessment of allocation concealment, all trials were scored and entered using the following principles:<BR/>Grade A: Adequate concealment<BR/>Grade B: Uncertain<BR/>Grade C: Clearly inadequate concealment</P>
<P>2. Quality assessment. Quality was assessed using a 5 part score (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>) and summarised as follows:<BR/>Was the study described as randomised (1=yes; 0=no)<BR/>Was the study described as double-blind (1=yes; 0=no)<BR/>Was there a description of withdrawals and dropouts (1=yes; 0=no)<BR/>Was the method of randomisation well described and appropriate (1=yes; 0=no)<BR/>Was the method of double blinding well described and appropriate (1=yes; 0=no)<BR/>Points were deducted for either inappropriate randomisation or blinding.</P>
</QUALITY_ASSESSMENT>
<MISSING_DATA MODIFIED="2008-07-23 09:48:17 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Attempts were made to contact the primary investigators of included studies to obtain individual patient data, however this was largely unsuccessful.</P>
<P>When the standard deviation (SD) for a measure was missing from a study, an estimate was imputed. The estimate was based on the weighted average (by sample size) of the deviations from other included studies for that category. Data from several studies were not reported in tabular format; however, they were demonstrated in charts. To extract these data values the graphs were enlarged and data points were extracted using exact calipers; results were checked for reliability twice. Some graphs and tables displayed a point estimate measure with standard errors of the mean (SEM). SEM's for these trials were converted to SD's thus: SD(Xbar) = SEM(Xbar)*sqrt(n).</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2011-03-09 11:29:35 +0000" MODIFIED_BY="Emma J Welsh">
<P>For pooled effects, heterogeneity was tested using the Breslow-Day test; in settings where the chi-square heterogeneity statistic revealed a P &lt; 0.1, a random effects model was reported. Sensitivity analyses were conducted on fixed vs. random effects models and methodological quality (high vs. low).</P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2008-07-23 09:49:02 +0100" MODIFIED_BY="Toby J Lasserson">
<P>All trials were combined using the RevMan. For continuous outcomes, individual and pooled statistics were calculated as weighted mean differences (WMD) and 95% confidence intervals (CIs) using a fixed effect model. For dichotomous variables, individual and pooled statistics were calculated as relative risks (RR) with 95% CIs; again, a fixed effect model was used. </P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2008-07-23 09:48:56 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Three specific subgroups were planned a priori: (a) patient age (adults vs. children); (b) acute asthma severity (severe vs. not severe); and (c) type of continuous nebuliser (commercially available model vs. intermittent nebuliser with infusion pump). A two-sided p-value &lt; 0.05 was considered statistically significant.</P>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-03-09 16:47:12 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2011-03-09 16:47:12 +0000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2011-03-09 16:47:12 +0000" MODIFIED_BY="[Empty name]">
<P>The original search in 1999 revealed 165 abstracts from trials; all were reviewed and 26 potentially relevant studies were identified (kappa = 1.0). In addition, from the CCTR search, 42 abstracts, and 10 potentially relevant studies were identified (kappa = 0.94). In 2002 an updated search revealed two additional studies (<LINK REF="STD-Besbes_x002d_Ouanes-2000" TYPE="STUDY">Besbes-Ouanes 2000</LINK>; <LINK REF="STD-Innes-2002" TYPE="STUDY">Innes 2002</LINK>). One excluded study has been added to the review from searches between 2002 and 2009. The current systematic review includes Register search updates to February 2011. The 2011 update search returned a potentially eligible abstract and we await publication in full (<LINK REF="STD-Rose-2010" TYPE="STUDY">Rose 2010</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2008-07-24 08:49:52 +0100" MODIFIED_BY="Toby J Lasserson">
<P>All studies were published after 1990; six were from centres in the United States, one each was from Canada and Tunisia. All studies were convenience or consecutive patients from a single centre. Overall, the studies enrolled small samples (range: 22-170 patients) with all but 2 under 100 patients.</P>
<P>Populations: One study enrolled children (<LINK REF="STD-Khine-1996" TYPE="STUDY">Khine 1996</LINK>), one enrolled a mix of adults and children (<LINK REF="STD-Reisner-1995" TYPE="STUDY">Reisner 1995</LINK>), and 6 enrolled adults only (<LINK REF="STD-Colacone-1990" TYPE="STUDY">Colacone 1990</LINK>; <LINK REF="STD-Lin-1993" TYPE="STUDY">Lin 1993</LINK>; <LINK REF="STD-Rudnitsky-1993" TYPE="STUDY">Rudnitsky 1993</LINK>; <LINK REF="STD-Shrestha-1996" TYPE="STUDY">Shrestha 1996</LINK>; <LINK REF="STD-Besbes_x002d_Ouanes-2000" TYPE="STUDY">Besbes-Ouanes 2000</LINK>; <LINK REF="STD-Innes-2002" TYPE="STUDY">Innes 2002</LINK>). The populations varied from patients with mild-moderate acute asthma (n = 3), to only those with "severe" attacks only (n = 5). Examination of the definitions used to designate the severe group reveals that patients had a combination of clinical findings, airflow measurements, or response to therapy that placed them in the severe category. The unadjusted admission proportion in the placebo group was 40% in the severe group vs. 11% in the mild-moderate group, which serves to partially validate this subgroup designation.</P>
<P>Interventions: Continuous inhaled beta-agonist treatment was administered early in the course of the ED treatment. One study used a small volume nebuliser and by increasing the amount of normal saline lengthened the nebulisation to 20 minutes, thereby creating back-to-back treatments and an effectively continuous nebulisation under these research conditions. The dosage of beta-agonist varied across studies; however, the dose of continuous beta-agonist (CBA) and intermittent beta-agonists administered were equivalent over the course of the studies. The dose in adults ranged from 5 mg to 30 mg and was generally administered over 120 minutes. In the sole pediatric study, children received 15 mg (<LINK REF="STD-Khine-1996" TYPE="STUDY">Khine 1996</LINK>). The studies lasted from 110 minutes (<LINK REF="STD-Lin-1993" TYPE="STUDY">Lin 1993</LINK>) to 6 hours (<LINK REF="STD-Besbes_x002d_Ouanes-2000" TYPE="STUDY">Besbes-Ouanes 2000</LINK>).</P>
<P>Co-interventions: Co-interventions were reported in all studies. Theophylline administration was not permitted (n = 3) or not reported (n = 3) in most studies. Corticosteroids were routinely administered to all patients in most studies (n = 6; <LINK REF="STD-Besbes_x002d_Ouanes-2000" TYPE="STUDY">Besbes-Ouanes 2000</LINK>; <LINK REF="STD-Innes-2002" TYPE="STUDY">Innes 2002</LINK>; <LINK REF="STD-Reisner-1995" TYPE="STUDY">Reisner 1995</LINK>; <LINK REF="STD-Khine-1996" TYPE="STUDY">Khine 1996</LINK>; <LINK REF="STD-Shrestha-1996" TYPE="STUDY">Shrestha 1996</LINK>), and at the discretion of physicians in older studies (n = 2; <LINK REF="STD-Colacone-1990" TYPE="STUDY">Colacone 1990</LINK>; <LINK REF="STD-Lin-1993" TYPE="STUDY">Lin 1993</LINK>). Supplemental oxygen was routinely administered in two studies (<LINK REF="STD-Besbes_x002d_Ouanes-2000" TYPE="STUDY">Besbes-Ouanes 2000</LINK>; <LINK REF="STD-Shrestha-1996" TYPE="STUDY">Shrestha 1996</LINK>). Ipratropium bromide was administered at the discretion of the treating physician in one study (<LINK REF="STD-Besbes_x002d_Ouanes-2000" TYPE="STUDY">Besbes-Ouanes 2000</LINK>).</P>
<P>Outcomes: Outcomes were determined at variable times, but usually included a variety of pulmonary function results and admission to hospital or discharge to home. Short-term follow-up (up to 6 hours) was provided in all studies and at intermediate times (up to 24 hours) in several (<LINK REF="STD-Innes-2002" TYPE="STUDY">Innes 2002</LINK>; ) to determine the rate of relapse to additional care. However, the variability of treatment approaches following discharge makes comparisons problematic after discharge. Adverse effects and vital signs were reported frequently enough to permit pooling. There were limited alternative outcomes such as symptom scores and quality of life measure; no economic endpoints were reported.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2008-07-23 09:50:13 +0100" MODIFIED_BY="Toby J Lasserson">
<P>See <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>. </P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-07-24 08:49:52 +0100" MODIFIED_BY="Toby J Lasserson">
<P>A full manuscript was available from each study on which to base quality assessments. Overall, the methodological quality of the included studies was rated as poor. Randomisation was poorly described in most studies. No studies were double-blind and only two were single-blind (<LINK REF="STD-Besbes_x002d_Ouanes-2000" TYPE="STUDY">Besbes-Ouanes 2000</LINK>; <LINK REF="STD-Reisner-1995" TYPE="STUDY">Reisner 1995</LINK>); all were controlled. However, few reported clearly on concealment of allocation, and many reported an insufficient number of outcomes. Four studies were rated as "strong" using the Jadad (scores = 3-5) method (<LINK REF="STD-Lin-1993" TYPE="STUDY">Lin 1993</LINK>; <LINK REF="STD-Reisner-1995" TYPE="STUDY">Reisner 1995</LINK>; <LINK REF="STD-Rudnitsky-1993" TYPE="STUDY">Rudnitsky 1993</LINK>; <LINK REF="STD-Besbes_x002d_Ouanes-2000" TYPE="STUDY">Besbes-Ouanes 2000</LINK>), and 4 were rated as "weak" (<LINK REF="STD-Colacone-1990" TYPE="STUDY">Colacone 1990</LINK>; <LINK REF="STD-Khine-1996" TYPE="STUDY">Khine 1996</LINK>; <LINK REF="STD-Shrestha-1996" TYPE="STUDY">Shrestha 1996</LINK>; <LINK REF="STD-Innes-2002" TYPE="STUDY">Innes 2002</LINK>). Using the Cochrane methodology, 2 studies were rated as blinded allocation (<LINK REF="STD-Innes-2002" TYPE="STUDY">Innes 2002</LINK>; <LINK REF="STD-Besbes_x002d_Ouanes-2000" TYPE="STUDY">Besbes-Ouanes 2000</LINK>) while 5 studies were rated as having unclear allocation (<LINK REF="STD-Colacone-1990" TYPE="STUDY">Colacone 1990</LINK>; <LINK REF="STD-Lin-1993" TYPE="STUDY">Lin 1993</LINK>; <LINK REF="STD-Reisner-1995" TYPE="STUDY">Reisner 1995</LINK>; <LINK REF="STD-Rudnitsky-1993" TYPE="STUDY">Rudnitsky 1993</LINK>; <LINK REF="STD-Shrestha-1996" TYPE="STUDY">Shrestha 1996</LINK>). In one study, allocation was clearly unblinded (<LINK REF="STD-Khine-1996" TYPE="STUDY">Khine 1996</LINK>).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2011-03-09 11:29:37 +0000" MODIFIED_BY="Emma J Welsh">
<P>Results from this meta-analysis are reported by outcome. The main results are reported as overall effects of continuous vs. intermittent inhaled beta-agonist. In addition, the main subgroup based on asthma severity is also reported.</P>
<SUBSECTION>
<HEADING LEVEL="5">ED Pulmonary Function Results</HEADING>
<P>A variety of short-term pulmonary function tests were reported in the included trials. Most commonly, PEFR and FEV-1 were reported at the completion of the trial (or as close to 6 hours as possible). Patients receiving CBA demonstrated significant improvements in PEFR (SMD = 0.33; 95% CI: 0.1 to 0.5, <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>), absolute FEV-1 (WMD = 0.37; 95% CI: 0.1 to 0.6), and % predicted FEV-1 (WMD = 0.28; 95% CI: 0.03 to 0.5) when all studies were pooled (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). No statistically significant heterogeneity was identified for the results when all studies were pooled using PEFR (P= 0.57), FEV-1 (P = 0.61) or % predicted FEV-1 (P = 0.45). Insufficient information was available to dissect these data to examine response based on severity of disease at presentation.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Time course of ED Pulmonary Function Improvements</HEADING>
<P>Sufficient information was available to examine the time course for the changes observed at the end of the trial period reported above. In the first 60 minutes, differences between CBA and intermittent treatment were not obvious in PEFR (SMD: 0.14; 95% CI: -0.05 to 0.3) and were small when FEV-1 was reported (SMD: 0.30; 95% CI: 0.05 to 0.5). By 2-3 hours, the difference was significant in both measures, favouring treatment with CBA (PEFR SMD: 0.37; 95% CI: 0.2 to 0.6; FEV-1 SMD: 0.33; 95% CI: 0.1 to 0.6). There were a limited number of studies (n = 3) which reported times beyond 4 hours, making results from this group less reliable. Nonetheless, the PEFR and FEV-1 SMDs were insignificant at 4-6 hours.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Admission to Hospital</HEADING>
<P>A significant difference was identified between patients treated with CBA vs. intermittent beta-agonist with respect to hospital admission at the end of the study period (RR: 0.68; 95% CI: 0.5 to 0.9). This result was similar if they were displayed as a odds ratio (OR: 0.57; 95% CI: 0.4 to 0.9) or number needed to treat (NNT: 10; 95% CI: 6, 34). This pooled result demonstrated no significant heterogeneity (chi square = 5.6; df = 7; P = 0.58). There was no apparent difference in hospitalisation for the studies where participants had mild-moderate asthma (RR: 1.12; 95% CI: 0.4 to 2.9); however, the confidence intervals are wide and the sample is small. Patients with severe asthma had fewer hospital admissions when treated with CBA (RR: 0.64; 95% CI: 0.5 to 0.9). This pooled result did not demonstrate significant heterogeneity (chi square = 2.95; df = 4; P = 0.56).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Tolerability</HEADING>
<P>Vital signs were recorded and reported in many of the included studies; pooled results did not demonstrate statistical or clinical heterogeneity. Continuous treatment was generally well tolerated, with no clinically important differences observed in pulse rate (WMD: -2.87; 95% CI: -6.1 to 0.3) or respiratory rate (WMD: 1.00; 95% CI: -1.6 to 3.6) between the treatment groups. Systolic blood pressure was similar in both groups (WMD: -1.75; 95% CI: -6.6 to 2.1); however, this result demonstrated heterogeneity and is reported using a random effects model. Overall, vital signs remained "stable" during the period immediately after treatment with CBA.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Side Effects</HEADING>
<P>Some side effect monitoring was common in these studies, but comprehensive lists of adverse events were rarely reported. CBA appears to be a safe treatment approach for acute asthma; general adverse events were similarly rare across multiple trials (WMD = 0.2; 95% CI: 0.03 to 1.6). Four trials (n = 307 patients) reported tremor as a specific side effect; pooled results failed to demonstrate differences between treatment groups (RR: 0.81; 95% CI: 0.5 to 1.3). Nausea and palpitations were reported in only one trial each; however, in both cases, these side effects were more common in the intermittent beta-agonists group than the CBA group. Potassium concentrations were reported in 3 trials and pooled results failed to demonstrate differences between treatment groups (WMD: 0.02; 95% CI: -0.2 to 0.2). However, an insufficient number of studies were available to provide meaningful sensitivity or sub-group comparisons, or firm conclusions about side effects or adverse events.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Subgroup/Sensitivity Analyses</HEADING>
<P>Due to an insufficient number of paediatric trials, a subgroup analysis based on age was not possible. The random (RE) and fixed effects (FE) models did not affect reported results; especially for the admission data where sufficient trials reported this outcome (FE RR: 0.68; 95% CI: 0.5 to 0.9 vs RE RR: 0.69; 95% CI: 0.5 to 0.9). Higher severity at initial presentation appeared to increase the response to CBA (RR: 0.64; 95% CI: 0.5 to 0.9). Finally, study quality was not found to influence pooled results for admissions. With all trials included in the analysis the OR = 0.57 (95% CI: 0.34 to 0.9) compared to OR = 0.55 (95% CI: 0.4 to 0.9) when the weakest trials were excluded.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-07-23 09:55:21 +0100" MODIFIED_BY="Toby J Lasserson">
<P>This systematic review examined the use of continuous nebulised beta-agonists in the ED management of acute asthma. The pooled results demonstrate a modest (effect size = 0.3), yet statistically significant beneficial effect of CBA in terms of pulmonary functions by 2-3 hours of therapy. The clinical significance of the magnitude of this pulmonary function improvement is difficult to determine, since the minimally clinically important difference for pulmonary functions in acute asthma have been infrequently studied. However, in chronic asthma an improvement of 12% predicted has been used (<LINK REF="REF-NAEPP-1997" TYPE="REFERENCE">NAEPP 1997</LINK>) and for acute studies, some have suggested an increase in PEFR of 30 L/min is clinically important (<LINK REF="REF-Tiffany-1993" TYPE="REFERENCE">Tiffany 1993</LINK>). The improvement of approximately 10% predicted FEV-1 or 50 L/min PEFR represent what we believe are important PF changes, especially considering the severity at the start of therapy. Moreover, these PFT changes appear important enough to reduce admissions. The effect of CBA can be restated using NNT as follows: 10 patients would have to receive CBA to prevent 1 admission to hospital, compared to intermittent beta-agonist nebulisation.</P>
<P>While the CBA delivery was well tolerated, with good efficacy in patients with severe asthma, its possible expense compared to other therapies and its more complex nature argues against its indiscriminate use in the emergency department treatment of acute asthma. Despite the lack of cost data, changing treatment approaches across EDs for all patients would not be appropriate; however, there is considerable evidence to suggest that the sub-group of patients presenting with severe acute asthma respond differently to the use of CBA. Patients who presented with severe asthma benefit from the use of CBA, both in terms of pulmonary functions and admission rates.</P>
<SUBSECTION>
<HEADING LEVEL="6">LIMITATIONS</HEADING>
<P>There is a possibility of publication bias in this meta-analysis. For example, by missing unpublished negative trials we may be over-estimating the efficacy of CBA treatment. However, a comprehensive search of the published literature for potentially relevant studies was conducted, using a systematic strategy to avoid bias. This was followed by attempts to contact corresponding and first authors. No unpublished trial was identified; however, several negative trials were uncovered. While we recognise that more of these types of trials may exist, the funnel plot for admission provide some additional reassurance that publication bias was not a threat to the conclusions reported here.</P>
<P>There is also a possibility of study selection bias. However, we employed two independent reviewers, and feel confident that the studies excluded were done so for consistent and appropriate reasons. Our search was comprehensive and has been updated, so it is unlikely that there are any trials in publication which were missed.</P>
<P>Finally, these results are discordant from the results presented in a published systematic review (<LINK REF="REF-Rodrigo-2002" TYPE="REFERENCE">Rodrigo 2002</LINK>). These authors claimed equivalence of CBA and such a claim is difficult to understand given the wide confidence intervals and small number of trials they presented. Such evidence does not demonstrate "equivalence"; rather, it supports the conclusion of a "lack of evidence of benefit" for the treatment. Our systematic review included more studies (8 vs 6) and this may explain the benefit demonstrated here with respect to admissions (RR: 0.69; 95% CI: 0.52 to 0.93). This result is compared to the reported "equivalence" (RR = 0.68; 95% CI: 0.33 to 1.38) by the earlier review (<LINK REF="REF-Rodrigo-2002" TYPE="REFERENCE">Rodrigo 2002</LINK>).</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<UL>
<LI>Most patients who present for assessment and treatment with an asthmatic exacerbation do not benefit from early treatment with CBA compared to intermittent beta-agonists in the emergency department.</LI>
<LI>In patients with "severe" acute asthma, benefits (e.g. pulmonary function improvements, reduced admissions) from treatment with CBA were observed. A practical clinical approach may be to identify those patients who fail to respond to initial beta-agonists or who have severe airflow limitations in the ED as being candidates for CBA therapy.</LI>
<LI>In addition to the CBA intervention, standard acute asthma therapy must be administered to these patients early in the ED treatment (including corticosteroids, oxygen, ipratropium bromide, etc.). </LI>
<LI>In this review, CBA nebulisation was provided as 5-15 mg over the first hour in adults, with lower doses in children. </LI>
<LI>Only 1 study was identified which examined the use of CBA in children. Given the small numbers involved in this study, readers should be cautious when extrapolating results to children, especially the very young.</LI>
</UL>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Many questions regarding the treatment of acute asthma with CBA remain unanswered. <BR/>
</P>
<UL>
<LI>Additional research is required to determine the optimal dose (high vs low) and duration of therapy. </LI>
<LI>Additional studies are needed to confirm the sub-group findings from this review suggesting a beneficial effect of CBA in severe acute asthma. In future studies, severity must be clearly defined and based on presenting pulmonary function results AND response to initial beta-agonist therapy whenever possible.</LI>
<LI>Studies involving very young children need to be performed to determine the effect of CBA in this age group.</LI>
<LI>Future research should examine the effect of CBA while maximising the use of known effective co-intervention therapies in acute asthma (e.g., systemic corticosteroids, inhaled corticosteroids, IV MgSO4, ipratropium bromide, etc). The effect of CBA treatment may differ based on administration of these therapies.</LI>
<LI>Future research on acute asthma must concentrate on well defined outcomes which may lead to more informative reviews in the future. More specifically, criteria for admission/discharge and reporting of pulmonary function data in a systematic fashion would assist in further work. Finally, better description of the methodology would also be beneficial.</LI>
</UL>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We wish to gratefully acknowledge the assistance provided by the members of the Cochrane Airways Group who helped with the protocol development, literature searches, and obtaining the studies (Steve Milan, Toby Lasserson and Karen Blackhall). We are grateful to Ms. Calacone for responding to our questions. Finally, we would also like to gratefully acknowledge the assistance of Dr. Chris Cates (ARG Technical and Criticism Editor) and Dr Paul Jones (ARG Coordinating Editor).</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>The authors who have been involved in this review have done so without any known conflicts of interest. They are neither involved with the primary studies nor affiliated with any pharmaceutical company that produces any of the continuous nebulizers.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Camargo CA Jr: Protocol development, study selection, analyses and interpretation of data, and write-up.<BR/>Spooner CH: data checking and entry, quality scoring, conversion to RevMan 4.1.<BR/>Rowe BH: Study selection, quality scoring, data extraction and entry, editing of manuscript, assigned editor.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-03-09 11:31:24 +0000" MODIFIED_BY="Emma J Welsh">
<STUDIES MODIFIED="2011-03-09 11:27:24 +0000" MODIFIED_BY="Emma J Welsh">
<INCLUDED_STUDIES MODIFIED="2008-07-24 08:50:47 +0100" MODIFIED_BY="Toby J Lasserson">
<STUDY DATA_SOURCE="PUB" ID="STD-Besbes_x002d_Ouanes-2000" NAME="Besbes-Ouanes 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Besbes-Ouanes L, Nouira S, Elatrous S, Knani J, Boussarsar M, Abroug F. Continuous versus intermittent nebulization of salbutamol in acute severe asthma: a randomized, controlled trial.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Besbes-Ouanes L, Nouira S, Elatrous S, Knani J, Boussarsar M, Abroug F</AU>
<TI>Continuous versus intermittent nebulization of salbutamol in acute severe asthma: a randomized, controlled trial</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>2000</YR>
<VL>36</VL>
<NO>3</NO>
<PG>236-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Colacone-1990" NAME="Colacone 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Colacone A, Wolkove N, Stern E, Afilalo M, Rosenthal TM, Kreisman H. Continuous nebulization of albuterol (Salbutamol) in acute asthma*. Chest 1990;97(3):693-697.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Colacone A, Wolkove N, Stern E, Afilalo M, Rosenthal TM, Kreisman H</AU>
<TI>Continuous nebulization of albuterol (salbutamol) in acute asthma</TI>
<SO>Chest</SO>
<YR>1990</YR>
<VL>97</VL>
<NO>3</NO>
<PG>693-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Innes-2002" MODIFIED="2008-07-23 10:00:15 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Innes 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-07-23 10:00:15 +0100" MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Innes NJ, Stocking JA, Daynes TJ, Harrison BD</AU>
<TI>Randomised pragmatic comparison of UK and US treatments of acute asthma presenting to the hospital</TI>
<SO>Thorax</SO>
<YR>2002</YR>
<VL>57</VL>
<NO>12</NO>
<PG>1040-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khine-1996" NAME="Khine 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Khine H, Fuchs SM, Saville AL. Continuous vs intermittent nebulized albuterol for emergency management of asthma. Academic Emergency Medicine 1996;3(11):1019-24.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khine H, Fuchs SM, Saville AL</AU>
<TI>Continuous vs intermittent nebulized albuterol for emergency management of asthma</TI>
<SO>Academic Emergeny Medicine</SO>
<YR>1996</YR>
<VL>3</VL>
<NO>11</NO>
<PG>1019-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-1993" NAME="Lin 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Lin RY, Sauter D, Newman T, Sirleaf J, Walters J, Tavakol M. Continuous versus intermittent albuterol nebulization in the treatment of acute asthma. Annals of Emergency Medicine 1993;22(12):1847-1853.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin RY, Sauter D, Newman T, Sirleaf J, Walters J, Tavakol M</AU>
<TI>Continuous versus intermittent albuterol nebulization in the treatment of acute asthma</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>1993</YR>
<VL>22</VL>
<NO>12</NO>
<PG>1847-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reisner-1995" NAME="Reisner 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Reisner C, Kotch A, Dworkin G. Continuous versus frequent intermittent nebulization of albuterol in acute asthma: a randomized, prospective study. Annals of Allergy, Asthma &amp;amp; Immunology 1995;75:41-47.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reisner C, Kotch A, Dworkin G</AU>
<TI>Continuous versus frequent intermittent nebulization of albuterol in acute asthma: a randomized, prospective study</TI>
<SO>Annals of Allergy Asthma and Immunology</SO>
<YR>1995</YR>
<VL>75</VL>
<PG>41-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rudnitsky-1993" NAME="Rudnitsky 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Rudnitsky GS, Eberlein RS, Schoffstall JM, Mazur JE, Spivey WH. Comparison of intermittent and continuously nebulized albuterol for treatment of asthma in an urban emergency department. Annals of Emergency Medicine 1993;22(12):1842-46.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rudnitsky GS, Eberlein RS, Schoffstall JM, Mazur JE, Spivey WH</AU>
<TI>Comparison of intermittent and continuously nebulized albuterol for treatment of asthma in an urban emergency department</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>1993</YR>
<VL>22</VL>
<NO>12</NO>
<PG>1842-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rudnitsky-1993a" NAME="Rudnitsky 1993a" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rudnitsky GS, Eberlein RS, Schoffstall JM, Mazur JE, Spivey WH</AU>
<TI>Comparison of intermittent and continuously nebulized albuterol for treatment of asthma in an urban emergency department</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>1993</YR>
<VL>22</VL>
<NO>12</NO>
<PG>1842-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shrestha-1996" MODIFIED="2008-07-24 08:50:31 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Shrestha 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-07-24 08:50:31 +0100" MODIFIED_BY="Toby J Lasserson" NOTES="&lt;p&gt;Shrestha M, Bidadi K, Gourlay S, Hayes J. Continuous vs intermittent albuterol, at high and low doses, in the treatment of severe acute asthma in adults*. Chest 1996;110:42-47.&lt;br&gt;(low dose continuous vs intermittent)&lt;/p&gt;" NOTES_MODIFIED="2008-07-24 08:50:31 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shrestha M, Bidadi K, Gourlay S, Hayes J</AU>
<TI>Continuous vs intermittent albuterol, at high and low doses, in the treatment of severe acute asthma in adults</TI>
<SO>Chest</SO>
<YR>1996</YR>
<VL>110</VL>
<NO>1</NO>
<PG>42-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shrestha-1996a" MODIFIED="2008-07-24 08:50:47 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Shrestha 1996a" YEAR="1996">
<REFERENCE MODIFIED="2008-07-24 08:50:47 +0100" MODIFIED_BY="Toby J Lasserson" NOTES="&lt;p&gt;Shrestha M, Bidadi K, Gourlay S, Hayes J. Continuous vs intermittent albuterol, at high and low doses, in the treatment of severe acute asthma in adults*. Chest 1996;110:42-47.&lt;br&gt;(high dose continuous vs intermittent)&lt;/p&gt;" NOTES_MODIFIED="2008-07-24 08:50:47 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shrestha M, Bidadi K, Gourlay S, Hayes J</AU>
<TI>Continuous vs intermittent albuterol, at high and low doses, in the treatment of severe acute asthma in adults</TI>
<SO>Chest</SO>
<YR>1996</YR>
<VL>110</VL>
<NO>1</NO>
<PG>42-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-02-19 09:38:05 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Andrews-2007" MODIFIED="2009-02-19 09:38:05 +0000" MODIFIED_BY="[Empty name]" NAME="Andrews 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-02-19 09:38:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andrews T, McGintee E, Tyler L, Mittal M, Chew A, Pawlowski N, Zorc J</AU>
<TI>Efficacy of high dose continuous nebulized levalbuterol for pediatric status asthmaticus [Abstract 956]</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2007</YR>
<VL>119</VL>
<NO>1 Suppl</NO>
<PG>S244</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levitt-1995" NAME="Levitt 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levitt MA, Gambrioli EF, Fink JB</AU>
<TI>Comparative trial of continuous nebulization versus metered-dose inhaler in the treatment of acute bronchospasm</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>1995</YR>
<VL>26</VL>
<NO>3</NO>
<PG>273-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moler-1988" NAME="Moler 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Moler FW, Hurwitz ME, Custer JR. Improvement in clinical asthma score and PaCO2 in children with severe asthma treated with continuously nebulized terbutaline. Journal Allergy Clinical Immunology 1988;81:1101-9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moler FW, Hurwitz ME, Custer JR</AU>
<TI>Improvement in clinical asthma score and PaCO2 in children with severe asthma treated with continuously nebulized terbutaline</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>1988</YR>
<VL>81</VL>
<PG>1101-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moler-1995" NAME="Moler 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Moler FW, Johnson CE, Laanen CV, Palmisano JM, Nasr SZ, Akingbola O. Continuous versus intermittent nebulized terbutaline: plasma levels and effects. American Journal Respiratory Critical Care Medicine 1995;151:602-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moler FW, Johnson CE, Laanen CV, Palmisano JM, Nasr SZ, Akingbola O</AU>
<TI>Continuous versus intermittent nebulized terbutaline: plasma levels and effects</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1995</YR>
<VL>151</VL>
<PG>602-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nelson-1990" NAME="Nelson 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Nelson MS, Hofstadter A, Parker J, Hargis C. Frequency of inhaled metaproterenol in the treatment of acute asthma exacerbation. Annals of Emergency Medicine 1990;19:21-25.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nelson MS, Hofstadter A, Parker J, Hargis C</AU>
<TI>Frequency of inhaled metaproterenol in the treatment of acute asthma exacerbation</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>1990</YR>
<VL>19</VL>
<PG>21-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oshlaker-1993" NAME="Oshlaker 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Olshaker J, Jerrard D, Barish RA, Brandt G, Hooper F. The efficacy and safety of a continuous albuterol protocol for the treatment of acute adult asthma attacks. American Journal of Emergency Medicine 1993;11:131-133.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olshaker J, Jerrard D, Barish RA, Brandt G, Hooper F</AU>
<TI>The efficacy and safety of a continuous albuterol protocol for the treatment of acute adult asthma attacks</TI>
<SO>American Journal of Emergency Medicine</SO>
<YR>1993</YR>
<VL>11</VL>
<PG>131-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Papo-1993" NAME="Papo 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Papo MC, Frank J, Thompson AE. A prospective, randomized study of continuous versus intermittent nebulized albuterol for severe status asthmaticus in children. Critical Care Medicine 1993;21:1479-1486.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Papo MC, Frank J, Thompson AE</AU>
<TI>A prospective, randomized study of continuous versus intermittent nebulized albuterol for severe status asthmaticus in children</TI>
<SO>Critical Care Medicine</SO>
<YR>1993</YR>
<VL>21</VL>
<PG>1479-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Portney-1988" NAME="Portney 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Portnoy J, Aggarwal J. Continuous terbutaline nebulization for the treatment of severe exacerbations of asthma in children. Annals of Allergy 1988;60:368-371.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Portnoy J, Aggarwal J</AU>
<TI>Continuous terbutaline nebulization for the treatment of severe exacerbations of asthma in children</TI>
<SO>Annals of Allergy</SO>
<YR>1988</YR>
<VL>60</VL>
<PG>368-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Portney-1992" NAME="Portney 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Portnoy J, Nadel G, Amado M, Willsie-Ediger S. Continuous nebulization for status asthmaticus. Annals of Allergy 1992;69:71-79.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Portnoy J, Nadel G, Amado M, Willsie-Ediger S</AU>
<TI>Continuous nebulization for status asthmaticus</TI>
<SO>Annals of Allergy</SO>
<YR>1992</YR>
<VL>69</VL>
<PG>71-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schuh-1989" NAME="Schuh 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Schuh S, Parkin P, Rajan A, Canny G, Healy R, Rieder M, et al. High- versus low-dose, frequently administered, nebulized albuterol in children with severe, acute asthma. Pediatrics 1989;83(4):513-518.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schuh S, Parkin P, Rajan A, Canny G, Healy R, Rieder M, et al</AU>
<TI>High- versus low-dose, frequently administered, nebulized albuterol in children with severe, acute asthma</TI>
<SO>Pediatric</SO>
<YR>1989</YR>
<VL>83</VL>
<NO>4</NO>
<PG>513-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stein-2003" NAME="Stein 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stein J, Levitt MA</AU>
<TI>A randomized controlled double-blind trial of usual-dose versus high-dose albuterol via continuous nebulization in patients with acute bronchospasm</TI>
<SO>Academic Emergency Medicine</SO>
<YR>2003</YR>
<VL>10</VL>
<PG>31-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weber-1999" NAME="Weber 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weber EJ, Levitt MA, Covington JK, Gambrioli E</AU>
<TI>Effect of continuously nebulized ipratropium bromide plus albuterol on emergency department length of stay and hospital admission rates in patients with acute bronchospasm. A randomized controlled trial</TI>
<SO>Chest</SO>
<YR>1999</YR>
<VL>115</VL>
<NO>4</NO>
<PG>937-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2011-03-09 11:27:24 +0000" MODIFIED_BY="Emma J Welsh">
<STUDY DATA_SOURCE="PUB" ID="STD-Rose-2010" MODIFIED="2011-03-09 11:27:24 +0000" MODIFIED_BY="Emma J Welsh" NAME="Rose 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-03-09 11:27:22 +0000" MODIFIED_BY="Emma J Welsh" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Rose JA; Cancelliere S; Matye P; Nair S; O'Riordan M</AU>
<TI>Comparison of a breath-actuated nebulizer versus a conventional continuous-output nebulizer in treating acute asthma in a pediatric emergency department: an ongoing randomized controlled trial [Abstract]</TI>
<SO>AAP National Conference and Exhibition</SO>
<YR>2010</YR>
<PG>11795</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-03-09 11:31:24 +0000" MODIFIED_BY="Emma J Welsh">
<ADDITIONAL_REFERENCES MODIFIED="2011-03-09 11:31:24 +0000" MODIFIED_BY="Emma J Welsh">
<REFERENCE ID="REF-Boulet-1999" MODIFIED="2008-07-23 09:52:33 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Boulet 1999" NOTES="&lt;p&gt;Boulet L-P, Becker A, Berube D, Beveridge RC, Ernst P on behalf of the Canadian Asthma Consensus Group. Canadian asthma consensus report, 1999. Can Med Assoc J 1999; 161:S1-S61.&lt;/p&gt;" NOTES_MODIFIED="2008-07-23 09:52:33 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Boulet LP, Becker A, Berube D, Beveridge RC, Ernst P, on behalf of the Canadian Asthma Consensus Group</AU>
<TI>Canadian asthma consensus report 1999</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1999</YR>
<VL>161</VL>
<PG>S1-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-BTS-1997" MODIFIED="2008-07-23 09:52:33 +0100" MODIFIED_BY="Toby J Lasserson" NAME="BTS 1997" NOTES="&lt;p&gt;The British guidelines on asthma management: 1995 review and position statement. Thorax 1997;52:152-156.&lt;/p&gt;" NOTES_MODIFIED="2008-07-23 09:52:33 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>BTS</AU>
<TI>The British guidelines on asthma management: 1995 review and position statement</TI>
<SO>Thorax</SO>
<YR>1997</YR>
<VL>52</VL>
<PG>152-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Camargo-1998" MODIFIED="2009-02-19 09:26:23 +0000" MODIFIED_BY="[Empty name]" NAME="Camargo 1998" NOTES="&lt;p&gt;Camargo CA Jr, on behalf of the MARC Investigators. Management of acute asthma in US emergency departments: The Multicenter Asthma Research Collaboration [abstract]. American Journal of Respiratory and Critical Care Medicine 1998;157.&lt;/p&gt;" NOTES_MODIFIED="2009-02-19 09:26:23 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Camargo CA Jr, on behalf of the MARC Investigators</AU>
<TI>Management of acute asthma in US emergency departments: The Multicenter Asthma Research Collaboration [abstract]</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1998</YR>
<VL>157</VL>
<NO>3 Suppl</NO>
<PG>A623</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cates-2006" MODIFIED="2009-02-19 09:31:12 +0000" MODIFIED_BY="[Empty name]" NAME="Cates 2006" NOTES="&lt;p&gt;Cates C, Rowe BH. Comparison of holding chambers and nebulisers for beta-agonists in acute asthma (Cochrane Review). In: Cochrane Library, Issue 3. 1998. Oxford: Update Software&lt;/p&gt;" NOTES_MODIFIED="2009-02-19 09:31:12 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="COCHRANE_REVIEW">
<AU>Cates C, Crilly JA, Rowe BH</AU>
<TI>Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma (Cochrane Review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2009-02-19 09:31:12 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-19 09:31:12 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000052.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-GINA-2002" MODIFIED="2008-07-23 09:52:33 +0100" MODIFIED_BY="Toby J Lasserson" NAME="GINA 2002" TYPE="BOOK">
<AU>NHLBI/WHO Workshop Report</AU>
<SO>Global Initiative on Asthma (GINA): Management and Prevention (available at: www.ginasthma.com)</SO>
<YR>2002</YR>
<EN>2nd</EN>
<PB>NIH Publication</PB>
<CY>Washington</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" MODIFIED="2008-07-23 10:09:35 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Jadad 1996" NOTES="&lt;p&gt;Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quailty of reports of randomized clinical trials: is blinding necessary? Controlled Clinical Trials 1996;17:1-12.&lt;/p&gt;" NOTES_MODIFIED="2008-07-23 10:09:35 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al</AU>
<TI>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mannino-1998" MODIFIED="2008-07-23 09:52:33 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Mannino 1998" NOTES="&lt;p&gt;Mannino DM, Homa DM, Pertowski, CA, Ashizawa A, Nixon LL, Johnson CA, Ball, LV, Jack E, Kang DS. Surveillance for asthma--United States, 1960-1995. Mor Mortal Wkly Rep 1998;47:1-27.&lt;/p&gt;" NOTES_MODIFIED="2008-07-23 09:52:33 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Mannino DM, Homa DM, Pertowski, CA, Ashizawa A, Nixon LL, Johnson CA, et al</AU>
<TI>Surveillance for asthma--United States, 1960-1995</TI>
<SO>Morbidity and Mortality Weekly Report</SO>
<YR>1998</YR>
<VL>47</VL>
<PG>1-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NAEPP-1997" MODIFIED="2008-07-23 09:52:33 +0100" MODIFIED_BY="Toby J Lasserson" NAME="NAEPP 1997" NOTES="&lt;p&gt;National Asthma Education and Prevention Program. Expert Panel Report II: Guidelines for the Diagnosis and Management of Asthma. 1997. Bethesda, MD, National Institutes of Health.&lt;/p&gt;" NOTES_MODIFIED="2008-07-23 09:52:33 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="BOOK_SECTION">
<AU>National Asthma Education and Prevention Program</AU>
<TI>Guidelines for the diagnosis and management of asthma</TI>
<SO>Expert Panel Report II</SO>
<YR>1997</YR>
<PB>National Institutes of Health</PB>
<CY>Bethesda, Md</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rodrigo-2002" MODIFIED="2008-07-23 09:52:33 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Rodrigo 2002" TYPE="JOURNAL_ARTICLE">
<AU>Rodrigo G, Rodrigo C</AU>
<TI>Continuous vs. intermittent B-agonists in the treatment of acute severe asthma: A systematic review with meta-analysis</TI>
<SO>Chest</SO>
<YR>2002</YR>
<VL>122</VL>
<PG>160-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rowe-1992" NAME="Rowe 1992" NOTES="&lt;p&gt;Rowe BH, Keller JL, Oxman AD. Steroid use in the emergency department treatment of asthma exacerbations: A meta-analysis. American Journal of Emergency Medicine. 1992;10:301-10.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Rowe BH, Keller JL, Oxman AD</AU>
<TI>Steroid use in the emergency department treatment of asthma exacerbations: A meta-analysis</TI>
<SO>American Journal of Emergency Medicine</SO>
<YR>1992</YR>
<VL>10</VL>
<PG>301-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rowe-2007" NAME="Rowe 2007" NOTES="&lt;p&gt;Rowe BH, Spooner CH, Ducharme FM, Bretzlaff JA, Bota GW. Corticosteroids for preventing relapse following acute exacerbations of asthma (Cochrane Review). In: Cochrane Library, Issue 1. 2001. Oxford: Update Software.&lt;/p&gt;" TYPE="COCHRANE_REVIEW">
<AU>Rowe BH, Spooner CH, Ducharme FM, Bretzlaff JA, Bota GW</AU>
<TI>Corticosteroids for preventing relapse following acute exacerbations of asthma (Cochrane Review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD000195. DOI: 10.1002/14651858.CD000195.pub2."/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Shultz-1995" MODIFIED="2008-07-23 09:52:33 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Shultz 1995" NOTES="&lt;p&gt;Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273:408-412.&lt;/p&gt;" NOTES_MODIFIED="2008-07-23 09:52:33 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tiffany-1993" MODIFIED="2008-07-23 09:52:33 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Tiffany 1993" NOTES="&lt;p&gt;Tiffany BR, Berk WA, Todd IK, White SR. Magnesium bolus or infusion fails to improve expiratory flow in acute asthma exacerbations. Chest 1993;104:831-834.&lt;/p&gt;" NOTES_MODIFIED="2008-07-23 09:52:33 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Tiffany BR, Berk WA, Todd IK, White SR</AU>
<TI>Magnesium bolus or infusion fails to improve expiratory flow in acute asthma exacerbations</TI>
<SO>Chest</SO>
<YR>1993</YR>
<VL>104</VL>
<PG>831-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Travers-2001" MODIFIED="2008-07-23 09:52:33 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Travers 2001" NOTES="&lt;p&gt;Travers A, Jones AP, Kelly K, Barker SJ, Camargo CA Jr., Rowe BH. Intravenous beta2-agonists for acute asthma in the emergency department (Cochrane Review). In: Cochrane Library, Issue 4, 2002. Oxford: Update Software.&lt;/p&gt;" NOTES_MODIFIED="2008-07-23 09:52:33 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="COCHRANE_REVIEW">
<AU>Travers A, Jones AP, Kelly K, Barker SJ, Camargo CA Jr., Rowe BH</AU>
<TI>Intravenous beta2-agonists for acute asthma in the emergency department (Cochrane Review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>1</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD002988. DOI: 10.1002/14651858.CD002988."/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Weiss-2001" MODIFIED="2008-07-23 09:52:33 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Weiss 2001" NOTES="&lt;p&gt;Weiss KB, Sullivan SD. The health economics of asthma and rhinitis. I. As economic impact. J Allergy Clin Immun 2001; 107:3-8.&lt;/p&gt;" NOTES_MODIFIED="2008-07-23 09:52:33 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Weiss KB, Sullivan SD</AU>
<TI>The health economics of asthma and rhinitis. I. As economic impact</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>2001</YR>
<VL>107</VL>
<PG>3-8</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2011-03-09 11:29:51 +0000" MODIFIED_BY="Emma J Welsh">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2011-03-09 11:29:51 +0000" MODIFIED_BY="Emma J Welsh" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-02-17 08:11:35 +0000" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Besbes_x002d_Ouanes-2000">
<CHAR_METHODS MODIFIED="2009-02-17 08:11:29 +0000" MODIFIED_BY="Toby J Lasserson">
<P>Design: RCT.<BR/>Method of randomisation: random numbers table, opaque envelopes.<BR/>Blinding: patients and treating MDs blind to treatment.<BR/>Objective: Safety &amp; efficacy of continuous salbutamol in ED tx of acute adult asthma.<BR/>Withdrawals: none described<BR/>Baseline: groups similar at the start of the study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: one hospital ED, Tunisia.<BR/>Recruitment: consecutive eligible pts.<BR/>Sample size: 42 (CN=21, IN =21)<BR/>Age: "adults"<BR/>Gender: 60% Female.<BR/>Inclusion: Dx asthma - clinical definition; &lt; 50% predicted PEFR plus 2 or more of: PR &gt; 119/min, RR&gt; 29/min, pulsus paradoxicus &gt; 14, accessory muscle use, SaO2 &lt; 92%, hypercapnia (&gt;42 mm Hg).<BR/>Exclusion: chronic cough, cardiac or hepatic disease, or pregnancy.<BR/>Severity: moderate-severe asthma.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Duration: 6 hrs.</P>
<P>Intervention: <BR/>Control: intermittent salbutamol 5mg q 20 minutes in 1st hour, then 2.5 mg hourly afterwards via pneumatic nebulization. Total given in 6 hrs = 27.5 mg salbutamol.</P>
<P>CBA: salbutamol 15mg over 1st hour, repeated 2.5 mg/hr for 5 hours via continuous pneumatic nebulizer. Total given in 6 hrs = 27.5 mg salbutamol.</P>
<P>Co-intervention: 200 mg IV hydrocortisone q4 hrs and oxygen at 6 L/min for all pts.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes reported:<BR/>Admission (to ICU or floor).<BR/>Clinical: 5-component scale.<BR/>PEFR: at 0. 40 min, 1, 3 and 6 hours.<BR/>Vital signs: PR, BP@ 60 &amp; 120 min<BR/>ADR: Potassium levels and ECG at 0 and 6 hrs. Arrhythmias (continuous monitoring) reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-17 08:11:35 +0000" MODIFIED_BY="Toby J Lasserson">
<P>Jadad Score: 3 Patients had to reach a set of criteria at 6 hours to achieve admission.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-09 11:29:39 +0000" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Colacone-1990">
<CHAR_METHODS MODIFIED="2011-03-09 11:29:39 +0000" MODIFIED_BY="Emma J Welsh">
<P>Design: RCT.<BR/>Method of randomisation: N/D<BR/>Objective: Safety &amp; efficacy of continuous albuterol in ED tx of acute adult asthma.<BR/>Withdrawals: 4/46, described<BR/>Baseline: BN group lower FEV1 values P=0.06) otherwise similar</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: General Hospital ED, Montreal, Canada.<BR/>Recruitment: consecutive eligible pts.<BR/>Sample size: 46 (CN=21, IN =21)<BR/>Age: &gt; 18 <BR/>Gender: 22M, 20F<BR/>Inclusion: Dx asthma - ATS criteria,<BR/>Exclusion: comorbidity: pneumonia, heart disease, diabetes, pregnant or nursing women<BR/>Severity: not described</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Duration: 2 hr.</P>
<P>Intervention: <BR/>Control: intermittent (BN)- albuterol 5.0mg (1.0mg diluted in 2.0mg saline) at time 0 &amp; 1 hr. via facemask &amp; Airlife-Misty Neb., 100% O2 at 8L/min x 10-15 min. Total given in 2 hrs = 10mg albuterol .</P>
<P>CBA: albuterol 100mg (20ml) in 480 ml saline continuously via facemask &amp; <BR/>Jet neb, O2 5-8 L/min. Total given in 2 hrs ~ 10.07 +- 0.52mg albuterol .<BR/>Co-intervention: only IV aminophylline &amp;/or corticosteroids allowed.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes reported:<BR/>FEV1: absolute values 0-120 min, % predicted 0-120 min<BR/>Vital signs: PR, RR, BP@30, 60, 90, 120 min<BR/>ADR: Tremor</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad Score: 2<BR/>Statistical issues: End of trial % predicted PFT calculated &amp; adjusted for baseline differences. Used baseline SD <BR/>Author contact:<BR/>ADRs: none noted</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Innes-2002">
<CHAR_METHODS>
<P>Design: RCT.<BR/>Method of randomisation: N/D<BR/>Objective: Safety &amp; efficacy of continuous albuterol in ED tx of acute adult asthma.<BR/>Withdrawals: not well described<BR/>Baseline: groups similar at the start of the study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: Two Hospital EDs, Ipswich, UK.<BR/>Recruitment: consecutive eligible pts.<BR/>Sample size: 170 CN=81, IN =89<BR/>Age: 18-64<BR/>Gender: 56% Female.<BR/>Inclusion: Dx asthma - clinical definition; &lt; or = to 75% predicted PEFR.<BR/>Exclusion: comorbidity: pregnancy, lung pathology, heart disease or arrhythmia, diabetes, status asthmaticus.<BR/>Severity: not described</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Duration: 2 hr.</P>
<P>Intervention: <BR/>Control: Oral prednisolone 40 mg; intermittent salbutamol 5.0mg (@ time 0) and 30 minutes) then q4 hourly nebulization. Total given in 2 hrs = 10 mg salbutamol.</P>
<P>CBA: 60 mg oral prednisolone. Salbutamol 10mg over 1 hour, repeated over the second hour continuously via nebulizer. Total given in 2 hrs ~ 20 mg albuterol .<BR/>Co-intervention: ipratropium bromide and IV beta-agonists were allowed.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes reported:<BR/>Admission, relapse if discharged, and length of stay is admitted.<BR/>PEFR: change at 1 and 2 hours<BR/>Vital signs: PR, BP@ 60 &amp; 120 min<BR/>ADR: Potassium levels and arrhythmias</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad Score: 2<BR/>This study had an in-patient component; however, we only examined the 2 hours data for this review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-23 10:06:45 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Khine-1996">
<CHAR_METHODS>
<P>Design: RCT, SB (treating physician).<BR/>Method of randomisation: block (poorly reported).<BR/>Objective: Safety &amp; efficacy of continuous albuterol in ED tx of acute asthma in children<BR/>Withdrawals: 3/73 were excluded.<BR/>Baseline groups similar.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-23 10:06:45 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Location: Pediatric ED, Philadelphia, USA.<BR/>Recruitment: children presenting to ED with mod - severe asthma exacerbation.<BR/>Sample size: 70 CN =35, IN =35<BR/>Age: ages 2-18, mean = 7.6 y (SD 4). Gender: 52 M, 18 F<BR/>Inclusion: At least 1 prior episode of wheezing<BR/>Exclusion: hypersensitivity to albuterol, pre-existing diagnosis with congenital heart disease, BPD, CF, sickle-cell disease, possible foreign body aspiration, corticosteroid therapy in the past 6 hours, use of subQ epinephrine in preceding 20 min., concurrent stridor &amp; wheeze, +ve RSV culture.<BR/>Severity: clinical asthma score &gt;=8</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>All received corticosteroids at entry.<BR/>Intervention: <BR/>Control: Control: albuterol 0.15 mg/kg/dose (minimum of 2.5 mg/dose and a maximum of 7.5 mg/dose) q 30 min. <BR/>Total dose /hr over 2 hours equivalent in both groups. <BR/>Maximum of 2 hours of treatment and 30 minutes of observation. </P>
<P>CBA: albuterol 0.3 mg/kg/hr (minimum 5 mg/hr, maximum 15mg/hr) achieved using facemask &amp; HEART nebulizer <BR/>Co-intervention: oral or intravenous corticosteroid. O2 via neb if pulse symmetry showed hypoxemia. Theophylline allowed.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes reported:<BR/>PEF: % mean change<BR/>Admission to hospital: criteria - persistent asthma score &gt;=8 and/or oxygen saturation &lt;94% on room air. Assessed independently by physician and investigator. <BR/>Vital signs: PR, RR, BP. Mean increase<BR/>ADR: tremor and vomiting <BR/>Timing: time in ED</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad Score: 2</P>
<P>Statistical issues: no baseline data to compute end of trial results<BR/>Author contact:</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-09 11:29:51 +0000" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Lin-1993">
<CHAR_METHODS>
<P>Design: RCT, <BR/>Method of randomisation: Computer generated pseudo-random numbers.<BR/>Blinding: non-blinded. Objective: Safety &amp; efficacy of continuous vs intermittent albuterol in ED tx of acute adult asthma exacerbation.<BR/>Withdrawals: none<BR/>Baseline groups similar.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: Public hospital ED, New York, USA. <BR/>Recruitment: volunteers<BR/>Sample size: 38 CN=19, IN=19<BR/>Age: 40.2 (SD 13.7) Gender: 20M, 18F<BR/>Inclusion: Dx of asthma by ATS criteria, smoked &lt; 20 pack yr of cigarettes, &gt;=18yr. <BR/>Severity: males with PEFR &lt;300 L/min., females with PEFRs &lt;250 L/min, pulse rate &lt;=180 per min,BP &lt;= 180/100 mm mercury.<BR/>Exclusion: Symptomatic angina pectorus or atherosclerotic heart disease, pregnancy, <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intervention: <BR/>Control: albuterol 5mg/ml (1ml in 2 ml saline) over 10 min. q 20 min. x 6 tx periods via facemask &amp; standard acorn-type jet neb. Delivered by pressurized O2 at 6-8 L/min.</P>
<P>CBA: albuterol 5MG/ML (6 ml in 34 ml saline) via facemask &amp; HEART system. Delivered by pressurized O2 at 10 L/min.</P>
<P>Both groups received 30 mg of albuterol over 110 min. <BR/>Co-intervention: Corticosteroids allowed. Aminophylline not allowed.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-03-09 11:29:51 +0000" MODIFIED_BY="Emma J Welsh">
<P>Outcomes reported:<BR/>FEV1: % predicted, absolute values 0 -110 min<BR/>Admission to hospital: no criteria applied.<BR/>Vital signs: PR.<BR/>ADRs: tremor, palpitations, agitation, headache.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad Score: 3<BR/>Statistical issues: 1 pt in CN recommended for admission but refused. Included as an admission. <BR/>Author contact: Correspondence pending from the author.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-02-17 08:11:48 +0000" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Reisner-1995">
<CHAR_METHODS>
<P>Design: RCT, SB (MD reading spirometry &amp; ECG tracings)<BR/>Method of randomisation: N/D<BR/>Objective: Safety &amp; efficacy of high dose CN neb albuterol vs high dose IN neb albuterol over 4 hrs<BR/>Withdrawals: 2/22. 1 pt from each group.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-17 08:11:48 +0000" MODIFIED_BY="Toby J Lasserson">
<P>Location: ED Danbury, Conneticut, USA.<BR/>Recruitment: adult asthmatics with acute asthma<BR/>Sample size: 22 CN=14, IN=8<BR/>Age: mean 34.5 y (SD 15) Gender: 5M, 15F<BR/>Inclusion: between 10-65 yr., PEFR less than 60% predicted.<BR/>Exclusions: Fever &gt; 100 F, &gt;10-pack year history of smoking. Pregnant or nursing mothers, women in child-bearing age. Intolerance to beta-agonists: co-morbid renal, cardiovascular, endocrine, hepatic, metabolic, neurologic or systemic disease prior to participation in this study.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intervention: <BR/>Control: 2.5 mg albuterol at time zero then q 20 min. x 4 hrs. Total= 30 mg in 12 Tx periods. The solution was administered via an Airlife Misty Nebulizer driven by 100% at a flow rate of 8 L/min.</P>
<P>CBA: 30 mg albuterol over 4 hours using a Travenol volumetric infusion pump. Nebulizer was driven by 100% oxygen at 8 L/ min. <BR/>Co-intervention: All received intravenous 125 mg of methyl- prednisolone on start of the study. No aminophylline.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes reported:<BR/>PEF, FEV-1: % change 0-240 min.<BR/>Vital signs: PR, RR, BP @ 240 min. <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad Score: 3<BR/>Statistical issues: Calculated end of trial result % predicted from % change scores. Used baseline SD. 1 pt (IN) recommended for admission but refused. Included as an admission. <BR/>Author contact: Pending author response.<BR/>ADR: 1 pt had abdominal pain, Tx group not specified.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-23 10:31:47 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Rudnitsky-1993">
<CHAR_METHODS MODIFIED="2008-07-23 10:31:47 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Design: RCT, non-blinded<BR/>Method of randomisation: block in groups of 10 Objective: Safety &amp; efficacy of continuous vs intermittent albuterol in ED tx of acute adult asthma exacerbation.<BR/>Withdrawals: 8. 4= &gt;1 enrolment, 4 lost to follow-up.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-23 10:31:45 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Location: ED Philadelphia, USA.<BR/>Recruitment: Consecutive eligible pts.<BR/>Sample size: 99. 47= CN, 52= IN.<BR/>Age: mean 35.5 y (SD14.5) Gender: 30M, 69F<BR/>Inclusion: Adults with an acute exacerbation of asthma (ATS criteria), &amp; a non-response to one tx of 2.5 mg neb albuterol<BR/>Exclusion: COPD, T &gt; 38.3C, evidence of pneumonia, heart failure, renal failure, pregnancy.<BR/>Severity: no severity rating.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intervention:<BR/>Control: 2.5 mg albuterol in 3ml saline via neb at time zero, 30, 60, 90 and 120 min.</P>
<P>CBA: 10 mg albuterol in 70 ml saline via Vortran Heart Nebulizer <BR/>Co-intervention: All received 2.5 mg neb albuterol and 125 mg of IV methylprednisolone. No other meds allowed.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes reported:<BR/>Clinical Scoring: official index at 120 minutes. <BR/>Hospital Admission <BR/>PEFR: absolute &amp; SD @ 0, 30, 60, 90, 120 min.<BR/>Vital signs: PR<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad Score: 3<BR/>Statistical issues: none<BR/>Author contact: Authors response still pending.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rudnitsky-1993a">
<CHAR_METHODS>
<P>Results from severe cases</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Shrestha-1996">
<CHAR_METHODS>
<P>Design: RCT, DB<BR/>Method of randomisation: N/D<BR/>Objective: Safety &amp; efficacy of high &amp; low dose albuterol via CN &amp; IN.<BR/>Withdrawals: none mentioned<BR/>Standard values<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: ED, U of Texas Medical Centre. USA<BR/>Recruitment: <BR/>Sample size: 157. CN: hi-dose =37, Std-dose =38, <BR/>IN: hi-dose = 40, std-dose = 42<BR/>Age: mean 34.4 (SD 10.6) Gender: 77 M, 80 F<BR/>Inclusion: Dx acute asthma: FEV1 &lt; 40% predicted, Dx &lt; 45 yrs.old, age =&gt;=18, <BR/>Exclusion: not pregnant, nursing or incarcerated, no Hx of allergy to albuterol, English speaking.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>4 groups Tx x 4 hr. <BR/>Intervention: <BR/>Control: hi-dose: 7.5 mg q 1h (1.5 ml in 1.5 ml saline) @ 6 L/min.<BR/>Control standard: 2.5 mg q 1h (0.5 ml in 2.5 ml saline).</P>
<P>CBA: hi-dose: 7.5 mg/h albuterol (1.5 ml in 13.5 ml saline)<BR/>CBA standard: 2.5 mg/h (0.5 ml in 14.5 ml saline) via Airlife Misty-neb @ 6L/min</P>
<P>Co-intervention: O2 if O2 sat &lt; 92%</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes reported:<BR/>FEV1: absolute, % predicted, % change @ 1 &amp; 2 hr.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad Score: 2<BR/>Statistical issues:<BR/>Author contact:</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-02-17 08:12:08 +0000" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Shrestha-1996a">
<CHAR_METHODS MODIFIED="2009-02-17 08:12:08 +0000" MODIFIED_BY="Toby J Lasserson">
<P>See Shrestha 1996<BR/>High dose-values</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>RCT = Randomised Control trial<BR/>DB = double blind<BR/>neb=nebuliser or nebulisation<BR/>N/D = not described<BR/>IN=intermittent nebulisation<BR/>CBA=continuous nebulisation<BR/>ADR = adverse reactions<BR/>PEF =Peak expiry flow<BR/>FEV1= forced expiratory flow in one second</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-02-17 08:13:27 +0000" MODIFIED_BY="Toby J Lasserson" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-02-17 08:13:27 +0000" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Andrews-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-17 08:13:27 +0000" MODIFIED_BY="Toby J Lasserson">
<P>Comparison of continuous racemic versus continuous levalbuterol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Levitt-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Continuous nebulization vs continuous metered dose inhaler with spacer in acute dyspnea. Mixed patient groups of COPD and asthma.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Moler-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series; not a randomized controlled trial and has no control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Moler-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>In-patient study of children with continuous agents delivered over 8 hours and more.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-07-23 10:09:26 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Nelson-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-23 10:09:26 +0100" MODIFIED_BY="Toby J Lasserson">
<P>No continuous arm of the trial; comparison of single to multiple doses.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Oshlaker-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>No control group; not a randomized controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Papo-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>In-patient study of pediatric patients admitted to the intensive care unit.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Portney-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series; not a randomized controlled trial and has no controls.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Portney-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schuh-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>High vs low dose "frequently" administered albuterol (not "continuous" vs intermittent)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stein-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Both groups received continuous nebulization.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Weber-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Continuous nebulization of albuterol plus ipratropium bromide compared to albuterol alone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>COPD = chronic obstructive pulmonary disease;<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2011-03-09 11:24:31 +0000" MODIFIED_BY="Emma J Welsh" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Rose-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES>
<P>We are not aware of any ongoing trials.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-02-17 08:11:55 +0000" MODIFIED_BY="Toby J Lasserson">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2008-07-24 08:49:52 +0100" MODIFIED_BY="Toby J Lasserson" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-23 09:57:36 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Besbes_x002d_Ouanes-2000">
<DESCRIPTION>
<P>Random numbers table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-23 09:57:59 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Colacone-1990">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-23 10:01:32 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Innes-2002">
<DESCRIPTION>
<P>Described as randomised by blocking</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-23 10:30:35 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Khine-1996">
<DESCRIPTION>
<P>Described as randomised by blocks. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-23 10:06:59 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Lin-1993">
<DESCRIPTION>
<P>Computer generated pseudo-random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-23 10:07:17 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Reisner-1995">
<DESCRIPTION>
<P>Described as randomised; no other information available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-23 10:07:42 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Rudnitsky-1993">
<DESCRIPTION>
<P>Described as randomised by blocking groups of 10</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-23 10:08:18 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Rudnitsky-1993a">
<DESCRIPTION>
<P>As for <LINK REF="STD-Rudnitsky-1993" TYPE="STUDY">Rudnitsky 1993</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-23 10:08:39 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Shrestha-1996">
<DESCRIPTION>
<P>Described as randomised; other information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-24 08:49:52 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Shrestha-1996a">
<DESCRIPTION>
<P>As for <LINK REF="STD-Shrestha-1996" TYPE="STUDY">Shrestha 1996</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-02-17 08:11:55 +0000" MODIFIED_BY="Toby J Lasserson" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-23 09:57:34 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Besbes_x002d_Ouanes-2000">
<DESCRIPTION>
<P>Opaque envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-23 09:58:04 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Colacone-1990">
<DESCRIPTION>
<P>Information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-23 10:02:02 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Innes-2002">
<DESCRIPTION>
<P>'sequential opaque sealed envelopes in<SUP> </SUP>which treatment allocation had been predetermined (...) by a statistician (EB) unconnected to the study.'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-23 10:31:32 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="NO" STUDY_ID="STD-Khine-1996">
<DESCRIPTION>
<P>Single-blind study; respiratory therapist administered treatment from behind curtain. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-23 10:07:05 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Lin-1993">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-23 10:07:22 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Reisner-1995">
<DESCRIPTION>
<P>Information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-17 08:11:55 +0000" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Rudnitsky-1993">
<DESCRIPTION>
<P>Information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-23 10:08:23 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Rudnitsky-1993a">
<DESCRIPTION>
<P>As for <LINK REF="STD-Rudnitsky-1993" TYPE="STUDY">Rudnitsky 1993</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-23 10:08:48 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Shrestha-1996">
<DESCRIPTION>
<P>Information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-24 08:49:52 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Shrestha-1996a">
<DESCRIPTION>
<P>As for <LINK REF="STD-Shrestha-1996" TYPE="STUDY">Shrestha 1996</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-07-23 09:52:32 +0100" MODIFIED_BY="Toby J Lasserson">
<COMPARISON ID="CMP-001" MODIFIED="2008-07-23 09:52:32 +0100" MODIFIED_BY="Toby J Lasserson" NO="1">
<NAME>Continuous vs intermittent nebulisation (end of study)</NAME>
<CONT_OUTCOME CHI2="2.9479771104635937" CI_END="0.5301177654418205" CI_START="0.1338979298808013" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.3320078476613109" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2008-07-23 09:52:28 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" P_CHI2="0.5665687722984872" P_Q="0.3327936669044841" P_Z="0.001021060513678967" Q="0.9379969581195517" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="197" TOTAL_2="204" UNITS="" WEIGHT="99.99999999999999" Z="3.28465849307848">
<NAME>PEFR values (end of study)</NAME>
<GROUP_LABEL_1>Continuous Tx</GROUP_LABEL_1>
<GROUP_LABEL_2>Intermittent Tx</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intermittent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours continuous</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.7550341135898893" CI_END="0.6429307553050465" CI_START="0.15866719322819894" DF="1" EFFECT_SIZE="0.4007989742666227" ESTIMABLE="YES" I2="43.021050573511715" ID="CMP-001.01.01" NO="1" P_CHI2="0.18524523935839587" P_Z="0.0011773383436156433" STUDIES="2" TAU2="0.0" TOTAL_1="128" TOTAL_2="141" WEIGHT="66.94356590582132" Z="3.244314113720238">
<NAME>Absolute PEFR</NAME>
<CONT_DATA CI_END="0.8338552789091006" CI_START="0.22129591472376464" EFFECT_SIZE="0.5275755968164326" ESTIMABLE="YES" MEAN_1="274.0" MEAN_2="243.0" ORDER="23" SD_1="64.0" SD_2="53.0" SE="0.15626801538628415" STUDY_ID="STD-Innes-2002" TOTAL_1="81" TOTAL_2="89" WEIGHT="41.83849561136839"/>
<CONT_DATA CI_END="0.584911040514611" CI_START="-0.2058686239088187" EFFECT_SIZE="0.18952120830289612" ESTIMABLE="YES" MEAN_1="310.0" MEAN_2="291.0" ORDER="24" SD_1="100.0" SD_2="99.0" SE="0.2017332131255979" STUDY_ID="STD-Rudnitsky-1993" TOTAL_1="47" TOTAL_2="52" WEIGHT="25.105070294452933"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.2549460387541528" CI_END="0.5372674929379612" CI_START="-0.15187370247768903" DF="2" EFFECT_SIZE="0.19269689523013608" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" NO="2" P_CHI2="0.880317172362274" P_Z="0.2730412005469356" STUDIES="3" TAU2="0.0" TOTAL_1="69" TOTAL_2="63" WEIGHT="33.05643409417867" Z="1.0960859025586496">
<NAME>% Predicted PEFR</NAME>
<CONT_DATA CI_END="0.802688613364698" CI_START="-0.4102357831760188" EFFECT_SIZE="0.19622641509433963" ESTIMABLE="YES" MEAN_1="62.0" MEAN_2="58.0" ORDER="25" SD_1="20.0" SD_2="20.0" SE="0.30942517467364444" STUDY_ID="STD-Besbes_x002d_Ouanes-2000" TOTAL_1="21" TOTAL_2="21" WEIGHT="10.670996166300757"/>
<CONT_DATA CI_END="0.7166137240384074" CI_START="-0.22418285433780444" EFFECT_SIZE="0.24621543485030145" ESTIMABLE="YES" MEAN_1="58.96" MEAN_2="56.48" ORDER="26" SD_1="10.3" SD_2="9.61" SE="0.24000353725810655" STUDY_ID="STD-Khine-1996" TOTAL_1="35" TOTAL_2="35" WEIGHT="17.73703276741119"/>
<CONT_DATA CI_END="0.8992527794508915" CI_START="-0.9384878884850747" EFFECT_SIZE="-0.01961755451709163" ESTIMABLE="YES" MEAN_1="61.94" MEAN_2="62.16" ORDER="27" SD_1="10.82" SD_2="10.58" SE="0.4688200095593159" STUDY_ID="STD-Reisner-1995" TOTAL_1="13" TOTAL_2="7" WEIGHT="4.648405160466724"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.786157042699934" CI_END="0.5047804870538641" CI_START="0.1474901459143741" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.3261353164841191" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2008-07-23 09:52:32 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="0.6711713645333457" P_Q="0.6193727446830319" P_Z="3.4607740424188614E-4" Q="0.24675020201251208" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="243" TOTAL_2="251" UNITS="" WEIGHT="200.0" Z="3.5781178542740952">
<NAME>FEV1 values (end of study)</NAME>
<GROUP_LABEL_1>Continuous</GROUP_LABEL_1>
<GROUP_LABEL_2>Internmittent</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intermittent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours continuous</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.8276295555316016" CI_END="0.6309503527353095" CI_START="0.11548624036557342" DF="3" EFFECT_SIZE="0.3732182965504415" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" NO="1" P_CHI2="0.6089411359596147" P_Z="0.004536913254723933" STUDIES="4" TAU2="0.0" TOTAL_1="115" TOTAL_2="122" WEIGHT="100.0" Z="2.838197275256916">
<NAME>Absoulte FEV1</NAME>
<CONT_DATA CI_END="0.9428205765483008" CI_START="-0.2761312940035071" EFFECT_SIZE="0.3333446412723968" ESTIMABLE="YES" MEAN_1="2.53" MEAN_2="2.2" ORDER="28" SD_1="1.02" SD_2="0.92" SE="0.3109628238495056" STUDY_ID="STD-Colacone-1990" TOTAL_1="21" TOTAL_2="21" WEIGHT="17.882315468802936"/>
<CONT_DATA CI_END="1.3528194258796837" CI_START="0.0387930630920682" EFFECT_SIZE="0.695806244485876" ESTIMABLE="YES" MEAN_1="2.43" MEAN_2="1.79" ORDER="29" SD_1="0.87" SD_2="0.93" SE="0.3352169665239994" STUDY_ID="STD-Lin-1993" TOTAL_1="19" TOTAL_2="19" WEIGHT="15.388231517450572"/>
<CONT_DATA CI_END="0.8903533577262999" CI_START="0.0013666017937142283" EFFECT_SIZE="0.4458599797600071" ESTIMABLE="YES" MEAN_1="1.91" MEAN_2="1.62" ORDER="30" SD_1="0.68" SD_2="0.61" SE="0.22678650295229905" STUDY_ID="STD-Shrestha-1996" TOTAL_1="38" TOTAL_2="42" WEIGHT="33.62066401625744"/>
<CONT_DATA CI_END="0.6189741073070526" CI_START="-0.2768583348961259" EFFECT_SIZE="0.1710578862054634" ESTIMABLE="YES" MEAN_1="1.95" MEAN_2="1.81" ORDER="31" SD_1="0.88" SD_2="0.74" SE="0.22853288358086946" STUDY_ID="STD-Shrestha-1996a" TOTAL_1="37" TOTAL_2="40" WEIGHT="33.10878899748906"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.71177728515582" CI_END="0.5304390435334092" CI_START="0.03475328829646601" DF="4" EFFECT_SIZE="0.28259616591493764" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" NO="2" P_CHI2="0.44641539165980937" P_Z="0.025430735087509843" STUDIES="5" TAU2="0.0" TOTAL_1="128" TOTAL_2="129" WEIGHT="100.0" Z="2.2347961445760065">
<NAME>Percent Predicted</NAME>
<CONT_DATA CI_END="1.170773508909579" CI_START="-0.06421896903493307" EFFECT_SIZE="0.553277269937323" ESTIMABLE="YES" MEAN_1="76.0" MEAN_2="65.0" ORDER="32" SD_1="19.0" SD_2="20.0" SE="0.31505489072400694" STUDY_ID="STD-Colacone-1990" TOTAL_1="21" TOTAL_2="21" WEIGHT="16.109581275658382"/>
<CONT_DATA CI_END="1.028362150718312" CI_START="-0.2565687434150633" EFFECT_SIZE="0.38589670365162443" ESTIMABLE="YES" MEAN_1="68.56" MEAN_2="60.06" ORDER="33" SD_1="17.22" SD_2="25.17" SE="0.327794516702538" STUDY_ID="STD-Lin-1993" TOTAL_1="19" TOTAL_2="19" WEIGHT="14.881727050552932"/>
<CONT_DATA CI_END="0.5039610576891811" CI_START="-1.3572724377302054" EFFECT_SIZE="-0.42665569002051223" ESTIMABLE="YES" MEAN_1="53.6" MEAN_2="59.15" ORDER="34" SD_1="12.92" SD_2="11.48" SE="0.47481318792094107" STUDY_ID="STD-Reisner-1995" TOTAL_1="13" TOTAL_2="7" WEIGHT="7.09269292724903"/>
<CONT_DATA CI_END="0.838736568914739" CI_START="-0.047837447504922304" EFFECT_SIZE="0.3954495607049084" ESTIMABLE="YES" MEAN_1="56.0" MEAN_2="48.6" ORDER="35" SD_1="18.0" SD_2="19.0" SE="0.22617099686852515" STUDY_ID="STD-Shrestha-1996" TOTAL_1="38" TOTAL_2="42" WEIGHT="31.25956133534256"/>
<CONT_DATA CI_END="0.5868564442551765" CI_START="-0.3083961672274741" EFFECT_SIZE="0.13923013851385116" ESTIMABLE="YES" MEAN_1="55.6" MEAN_2="53.0" ORDER="36" SD_1="19.0" SD_2="18.0" SE="0.22838496486269363" STUDY_ID="STD-Shrestha-1996a" TOTAL_1="37" TOTAL_2="40" WEIGHT="30.656437411197096"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="5.627122880357688" CI_END="0.9164833199798444" CI_START="0.5114992395487586" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6846754860726445" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="75" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.03787543480065384" LOG_CI_START="-0.29115500762146596" LOG_EFFECT_SIZE="-0.16451522121105994" METHOD="MH" MODIFIED="2008-07-23 09:52:32 +0100" MODIFIED_BY="Toby J Lasserson" NO="3" P_CHI2="0.5838981388713586" P_Q="0.0" P_Z="0.010891833425462938" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="229" TOTAL_2="232" WEIGHT="100.0" Z="2.546150128817826">
<NAME>Admission to hospital (end of observation period)</NAME>
<GROUP_LABEL_1>Continuous</GROUP_LABEL_1>
<GROUP_LABEL_2>Intermittent</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours continuous</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intermittent</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.964427885408907" CI_END="0.8730024398398085" CI_START="0.4717605286118054" DF="4" EFFECT_SIZE="0.6417539189582124" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="68" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="-0.058984542540152056" LOG_CI_START="-0.3262783985992054" LOG_EFFECT_SIZE="-0.19263147056967872" NO="1" P_CHI2="0.563795909639734" P_Z="0.004728263335762963" STUDIES="5" TAU2="0.0" TOTAL_1="169" TOTAL_2="172" WEIGHT="91.01399538715499" Z="2.8249863290695716">
<NAME>Moderate-severe</NAME>
<DICH_DATA CI_END="2.3476559929760374" CI_START="0.5391015565255851" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.37063445914385457" LOG_CI_START="-0.26832941424909207" LOG_EFFECT_SIZE="0.05115252244738129" ORDER="15" O_E="0.0" SE="0.3753305421532011" STUDY_ID="STD-Besbes_x002d_Ouanes-2000" TOTAL_1="21" TOTAL_2="21" VAR="0.14087301587301587" WEIGHT="10.729557746680614"/>
<DICH_DATA CI_END="0.9675979772258364" CI_START="0.3521380134328824" EFFECT_SIZE="0.5837191358024691" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="32" LOG_CI_END="-0.014305048206577542" LOG_CI_START="-0.4532870901441604" LOG_EFFECT_SIZE="-0.233796069175369" ORDER="16" O_E="0.0" SE="0.25786022443028944" STUDY_ID="STD-Innes-2002" TOTAL_1="81" TOTAL_2="89" VAR="0.06649189534323925" WEIGHT="40.89854952852375"/>
<DICH_DATA CI_END="1.4613734918282182" CI_START="0.32797224221495724" EFFECT_SIZE="0.6923076923076923" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.1647612253185304" LOG_CI_START="-0.4841629110535543" LOG_EFFECT_SIZE="-0.1597008428675119" ORDER="17" O_E="0.0" SE="0.3811812499312437" STUDY_ID="STD-Khine-1996" TOTAL_1="13" TOTAL_2="9" VAR="0.14529914529914528" WEIGHT="9.510289820921454"/>
<DICH_DATA CI_END="2.925270697442083" CI_START="0.03798318945602845" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.46616606083383155" LOG_CI_START="-1.4204085702731564" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="18" O_E="0.0" SE="1.1081832770072813" STUDY_ID="STD-Lin-1993" TOTAL_1="19" TOTAL_2="19" VAR="1.2280701754385965" WEIGHT="4.0235841550052305"/>
<DICH_DATA CI_END="0.997764833424064" CI_START="0.3170090938813779" EFFECT_SIZE="0.562406015037594" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="19" LOG_CI_END="-9.718069903611536E-4" LOG_CI_START="-0.49892827921488764" LOG_EFFECT_SIZE="-0.2499500431026244" ORDER="19" O_E="0.0" SE="0.29250209670897814" STUDY_ID="STD-Rudnitsky-1993" TOTAL_1="35" TOTAL_2="34" VAR="0.08555747657914842" WEIGHT="25.852014136023943"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.404711231501028" CI_END="2.8468625833562164" CI_START="0.44015578775029157" DF="2" EFFECT_SIZE="1.119402985074627" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.45436650447381194" LOG_CI_START="-0.35639358309206465" LOG_EFFECT_SIZE="0.04898646069087366" NO="2" P_CHI2="0.49541697734658974" P_Z="0.8127780690361943" STUDIES="3" TAU2="0.0" TOTAL_1="60" TOTAL_2="60" WEIGHT="8.986004612845015" Z="0.23684367337926773">
<NAME>Less severe</NAME>
<DICH_DATA CI_END="3.748275808525094" CI_START="0.11857303655019144" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5738315399834706" LOG_CI_START="-0.9260140580948332" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="20" O_E="0.0" SE="0.8810167286666446" STUDY_ID="STD-Khine-1996" TOTAL_1="35" TOTAL_2="35" VAR="0.7761904761904761" WEIGHT="4.0235841550052305"/>
<DICH_DATA CI_END="7.359855704568143" CI_START="0.03939490664503182" EFFECT_SIZE="0.5384615384615384" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.8668692997554162" LOG_CI_START="-1.404559924340576" LOG_EFFECT_SIZE="-0.26884531229257996" ORDER="21" O_E="0.0" SE="1.334248769989982" STUDY_ID="STD-Reisner-1995" TOTAL_1="13" TOTAL_2="7" VAR="1.7802197802197803" WEIGHT="1.7435531338355998"/>
<DICH_DATA CI_END="7.387503355312876" CI_START="0.5414549148222474" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.8684976911405519" LOG_CI_START="-0.26643769981258947" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="22" O_E="0.0" SE="0.6666666666666666" STUDY_ID="STD-Rudnitsky-1993" TOTAL_1="12" TOTAL_2="18" VAR="0.4444444444444444" WEIGHT="3.2188673240041843"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5546741762656335" CI_START="0.02572886371347662" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.1916393848247231" LOG_CI_START="-1.5895793934967606" LOG_EFFECT_SIZE="-0.6989700043360187" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.1239940474853702" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="142" TOTAL_2="150" WEIGHT="100.0" Z="1.5382232114837333">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Continuous</GROUP_LABEL_1>
<GROUP_LABEL_2>Intermittent</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours continuous</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intermittent</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="37" O_E="0.0" SE="0.0" STUDY_ID="STD-Besbes_x002d_Ouanes-2000" TOTAL_1="21" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38" O_E="0.0" SE="0.0" STUDY_ID="STD-Colacone-1990" TOTAL_1="21" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="39" O_E="0.0" SE="0.0" STUDY_ID="STD-Innes-2002" TOTAL_1="81" TOTAL_2="89" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.5546741762656335" CI_START="0.02572886371347662" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.1916393848247231" LOG_CI_START="-1.5895793934967606" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="40" O_E="0.0" SE="1.0462967275611939" STUDY_ID="STD-Lin-1993" TOTAL_1="19" TOTAL_2="19" VAR="1.0947368421052632" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.05" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="35" TOTAL_2="35" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>ED treatment time</NAME>
<GROUP_LABEL_1>Continuous</GROUP_LABEL_1>
<GROUP_LABEL_2>Intermittent</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours continuous</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intermittent</GRAPH_LABEL_2>
<CONT_DATA CI_END="11.501041261597065" CI_START="-13.501041261597065" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="123.0" MEAN_2="124.0" ORDER="41" SD_1="23.9" SD_2="29.2" SE="6.378199477237175" STUDY_ID="STD-Khine-1996" TOTAL_1="35" TOTAL_2="35" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.06" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="35" TOTAL_2="35" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Respiratory therapist time</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Continuous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intermittent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours continuous</GRAPH_LABEL_2>
<CONT_DATA CI_END="-17.17628101390889" CI_START="-26.82371898609111" EFFECT_SIZE="-22.0" ESTIMABLE="YES" MEAN_1="30.0" MEAN_2="52.0" ORDER="42" SD_1="4.0" SD_2="14.0" SE="2.461126339126632" STUDY_ID="STD-Khine-1996" TOTAL_1="35" TOTAL_2="35" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.2623418096540924" CI_END="0.8054930595696886" CI_START="0.051690540265740936" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.4285917999177148" ESTIMABLE="YES" I2="55.79801444093464" I2_Q="0.0" ID="CMP-001.07" NO="7" P_CHI2="0.13255359044405823" P_Q="1.0" P_Z="0.025829517301801278" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="56" TOTAL_2="56" UNITS="" WEIGHT="100.0" Z="2.228765413741484">
<NAME>Symptom scores</NAME>
<GROUP_LABEL_1>Continuous</GROUP_LABEL_1>
<GROUP_LABEL_2>Intermittent</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intermittent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours continuous</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.6704087686442052" CI_START="-0.5396637745236615" EFFECT_SIZE="0.06537249706027179" ESTIMABLE="YES" MEAN_1="6.3" MEAN_2="6.1" ORDER="43" SD_1="3.1" SD_2="2.9" SE="0.30869764768964236" STUDY_ID="STD-Besbes_x002d_Ouanes-2000" TOTAL_1="21" TOTAL_2="21" WEIGHT="38.80541707697687"/>
<CONT_DATA CI_END="1.1407254019405864" CI_START="0.17711585301839688" EFFECT_SIZE="0.6589206274794916" ESTIMABLE="YES" MEAN_1="7.0" MEAN_2="5.0" ORDER="44" SD_1="3.1" SD_2="2.9" SE="0.24582327954059835" STUDY_ID="STD-Khine-1996" TOTAL_1="35" TOTAL_2="35" WEIGHT="61.19458292302313"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.576232078642769" CI_END="0.19253255073296502" CI_START="-0.16133933319854063" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.015596608767212184" ESTIMABLE="YES" I2="56.29592281095225" I2_Q="0.0" ID="CMP-001.08" NO="8" P_CHI2="0.10145757148949186" P_Q="1.0" P_Z="0.8628341347965964" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.013728490022397571" TOTALS="YES" TOTAL_1="102" TOTAL_2="104" UNITS="" WEIGHT="100.0" Z="0.17276756279746902">
<NAME>Potassium concentration</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Continuous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intermittent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours continuous</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.041943206895663915" CI_START="-0.44194320689566424" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="3.4" MEAN_2="3.6" ORDER="45" SD_1="0.4" SD_2="0.4" SE="0.12344267996967354" STUDY_ID="STD-Besbes_x002d_Ouanes-2000" TOTAL_1="21" TOTAL_2="21" WEIGHT="28.134463744262508"/>
<CONT_DATA CI_END="0.2979376433914547" CI_START="-0.09793764339145541" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="4.0" ORDER="46" SD_1="0.46" SD_2="0.46" SE="0.10099044929027366" STUDY_ID="STD-Shrestha-1996" TOTAL_1="41" TOTAL_2="42" WEIGHT="34.05944079405642"/>
<CONT_DATA CI_END="0.27340758373108387" CI_START="-0.07340758373108461" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="3.8" MEAN_2="3.7" ORDER="47" SD_1="0.44" SD_2="0.35" SE="0.08847488275238787" STUDY_ID="STD-Shrestha-1996a" TOTAL_1="40" TOTAL_2="41" WEIGHT="37.806095461681075"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.711986773533273" CI_END="0.33843882153864024" CI_START="-6.073605669956249" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.8675834242088047" ESTIMABLE="YES" I2="15.110118252717243" I2_Q="0.0" ID="CMP-001.09" NO="9" P_CHI2="0.31814599053742487" P_Q="1.0" P_Z="0.0795911263663432" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="183" TOTAL_2="190" UNITS="" WEIGHT="100.0" Z="1.753063392360518">
<NAME>Pulse rate</NAME>
<GROUP_LABEL_1>Continuous</GROUP_LABEL_1>
<GROUP_LABEL_2>Intermittent</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours continuous</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intermittent</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.6777282758265635" CI_START="-16.677728275826563" EFFECT_SIZE="-7.0" ESTIMABLE="YES" MEAN_1="102.0" MEAN_2="109.0" ORDER="48" SD_1="16.0" SD_2="16.0" SE="4.937707198786941" STUDY_ID="STD-Besbes_x002d_Ouanes-2000" TOTAL_1="21" TOTAL_2="21" WEIGHT="10.97453719325315"/>
<CONT_DATA CI_END="7.468012241348243" CI_START="-9.468012241348243" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="95.0" MEAN_2="96.0" ORDER="49" SD_1="14.0" SD_2="14.0" SE="4.320493798938574" STUDY_ID="STD-Colacone-1990" TOTAL_1="21" TOTAL_2="21" WEIGHT="14.33408939526942"/>
<CONT_DATA CI_END="4.726313335825106" CI_START="-4.726313335825106" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="98.0" MEAN_2="98.0" ORDER="50" SD_1="16.4" SD_2="14.9" SE="2.41142866558042" STUDY_ID="STD-Innes-2002" TOTAL_1="81" TOTAL_2="89" WEIGHT="46.01379385243684"/>
<CONT_DATA CI_END="13.586149759258111" CI_START="-15.586149759258111" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="115.0" MEAN_2="116.0" ORDER="51" SD_1="13.7" SD_2="16.93" SE="7.442049891891789" STUDY_ID="STD-Reisner-1995" TOTAL_1="13" TOTAL_2="7" WEIGHT="4.831163399926536"/>
<CONT_DATA CI_END="-1.4346940106967399" CI_START="-14.56530598930326" EFFECT_SIZE="-8.0" ESTIMABLE="YES" MEAN_1="93.0" MEAN_2="101.0" ORDER="52" SD_1="18.0" SD_2="15.0" SE="3.3497074645705514" STUDY_ID="STD-Rudnitsky-1993" TOTAL_1="47" TOTAL_2="52" WEIGHT="23.846416159114053"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.550316286292185" CI_START="-1.550316286292185" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="1.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.10" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.4421795044509166" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="34" TOTAL_2="28" UNITS="" WEIGHT="100.0" Z="0.7685180050312805">
<NAME>Respiratory rate (end of study)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intermittent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours continuous</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.024290086195801" CI_START="-2.024290086195801" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="22.0" MEAN_2="21.0" ORDER="53" SD_1="5.0" SD_2="5.0" SE="1.5430334996209192" STUDY_ID="STD-Colacone-1990" TOTAL_1="21" TOTAL_2="21" WEIGHT="71.11172225867577"/>
<CONT_DATA CI_END="5.744967245744539" CI_START="-3.7449672457445393" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="18.0" MEAN_2="17.0" ORDER="54" SD_1="6.85" SD_2="3.97" SE="2.420946141445575" STUDY_ID="STD-Reisner-1995" TOTAL_1="13" TOTAL_2="7" WEIGHT="28.88827774132423"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.837139118469471" CI_END="2.046781351941461" CI_START="-5.550238247779933" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.7517284479192357" ESTIMABLE="YES" I2="82.8683199131597" I2_Q="0.0" ID="CMP-001.11" NO="11" P_CHI2="0.01569135580380332" P_Q="1.0" P_Z="0.3660691490482333" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="102" TOTAL_2="110" UNITS="" WEIGHT="100.00000000000003" Z="0.9038609479806687">
<NAME>Blood pressure (end of study)</NAME>
<GROUP_LABEL_1>Continuous</GROUP_LABEL_1>
<GROUP_LABEL_2>Intermittent</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intermittent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours continuous</GRAPH_LABEL_2>
<CONT_DATA CI_END="16.775653994113018" CI_START="-0.7756539941130178" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="131.0" MEAN_2="123.0" ORDER="55" SD_1="14.0" SD_2="15.0" SE="4.477456761111049" STUDY_ID="STD-Colacone-1990" TOTAL_1="21" TOTAL_2="21" WEIGHT="18.73559626733971"/>
<CONT_DATA CI_END="0.21369478427044708" CI_START="-8.213694784270448" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="91.0" MEAN_2="95.0" ORDER="56" SD_1="14.0" SD_2="14.0" SE="2.1498837823080086" STUDY_ID="STD-Innes-2002" TOTAL_1="81" TOTAL_2="89" WEIGHT="81.26440373266031"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="3.7171051245510536" CI_END="1.2814171638238638" CI_START="0.5072052868170683" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8061895311337137" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.10769053681213192" LOG_CI_START="-0.2948162282660846" LOG_EFFECT_SIZE="-0.09356284572697632" METHOD="MH" NO="12" P_CHI2="0.4456430612582035" P_Q="0.0" P_Z="0.3621959675344555" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="150" TOTAL_2="157" WEIGHT="100.0" Z="0.9111886995505077">
<NAME>Tremor</NAME>
<GROUP_LABEL_1>Continuous</GROUP_LABEL_1>
<GROUP_LABEL_2>Intermittent</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours continuous</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intermittent</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.465486804596542" CI_START="0.6492594336286757" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.5397642495395348" LOG_CI_START="-0.18758173142817242" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="57" O_E="0.0" SE="0.4272466296411038" STUDY_ID="STD-Colacone-1990" TOTAL_1="21" TOTAL_2="21" VAR="0.18253968253968256" WEIGHT="19.101959811461178"/>
<DICH_DATA CI_END="1.491738683213947" CI_START="0.20690083241903584" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.17369275183781935" LOG_CI_START="-0.6842377620444314" LOG_EFFECT_SIZE="-0.25527250510330607" ORDER="58" O_E="0.0" SE="0.5039526306789697" STUDY_ID="STD-Khine-1996" TOTAL_1="35" TOTAL_2="35" VAR="0.25396825396825395" WEIGHT="28.652939717191764"/>
<DICH_DATA CI_END="4.342888011770493" CI_START="0.23026152120195323" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.637778630537181" LOG_CI_START="-0.637778630537181" LOG_EFFECT_SIZE="0.0" ORDER="59" O_E="0.0" SE="0.7492686492653552" STUDY_ID="STD-Lin-1993" TOTAL_1="19" TOTAL_2="19" VAR="0.5614035087719298" WEIGHT="9.550979905730589"/>
<DICH_DATA CI_END="2.3648390438864793" CI_START="0.0322856710734054" EFFECT_SIZE="0.27631578947368424" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3738015870481517" LOG_CI_START="-1.4909901821418958" LOG_EFFECT_SIZE="-0.5585942975468721" ORDER="60" O_E="0.0" SE="1.0953879160903648" STUDY_ID="STD-Shrestha-1996" TOTAL_1="38" TOTAL_2="42" VAR="1.199874686716792" WEIGHT="12.097907880592079"/>
<DICH_DATA CI_END="1.7815421245936582" CI_START="0.3214522861914504" EFFECT_SIZE="0.7567567567567568" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.25079609570880806" LOG_CI_START="-0.49288348115835956" LOG_EFFECT_SIZE="-0.12104369272477575" ORDER="61" O_E="0.0" SE="0.4368410647250506" STUDY_ID="STD-Shrestha-1996a" TOTAL_1="37" TOTAL_2="40" VAR="0.19083011583011583" WEIGHT="30.596212685024394"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="19" TOTAL_2="19" WEIGHT="0.0" Z="0.0">
<NAME>Palpitations</NAME>
<GROUP_LABEL_1>Continuous</GROUP_LABEL_1>
<GROUP_LABEL_2>Intermittent</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours continuous</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intermittent</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.907878491633857" CI_START="0.01023573278586671" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5919410516605245" LOG_CI_START="-1.989881060332562" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="62" O_E="0.0" SE="1.5165750888103102" STUDY_ID="STD-Lin-1993" TOTAL_1="19" TOTAL_2="19" VAR="2.3000000000000003" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="35" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Nausea/vomiting</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours continuous</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intermittent</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.021183978262525" CI_START="0.009947319052356126" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6043539435123508" LOG_CI_START="-2.002293952184388" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="63" O_E="0.0" SE="1.531157877047447" STUDY_ID="STD-Khine-1996" TOTAL_1="35" TOTAL_2="35" VAR="2.3444444444444446" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Continuous vs Intermittent PFT time line</NAME>
<CONT_OUTCOME CHI2="7.971509257204436" CI_END="0.35712233303283514" CI_START="0.04833085263937337" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.20272659283610425" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.01" NO="1" P_CHI2="0.5370200490496095" P_Q="0.3501069059487406" P_Z="0.010067680901141124" Q="0.8730699766485586" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="325" TOTAL_2="332" UNITS="" WEIGHT="200.0" Z="2.573496005530943">
<NAME>Early ( 1 hour or less)</NAME>
<GROUP_LABEL_1>Continuous</GROUP_LABEL_1>
<GROUP_LABEL_2>Intermittent</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intermittent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours continuous</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.45826221867223" CI_END="0.3414402008263543" CI_START="-0.05294470150945049" DF="4" EFFECT_SIZE="0.14424774965845188" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.01" NO="1" P_CHI2="0.6521249359495809" P_Z="0.15164981815230408" STUDIES="5" TAU2="0.0" TOTAL_1="197" TOTAL_2="203" WEIGHT="100.0" Z="1.4337282817220482">
<NAME>PEFR</NAME>
<CONT_DATA CI_END="0.7271699695049455" CI_START="-0.4837810563487629" EFFECT_SIZE="0.12169445657809133" ESTIMABLE="YES" MEAN_1="44.0" MEAN_2="42.0" ORDER="64" SD_1="18.0" SD_2="14.0" SE="0.30892175453363824" STUDY_ID="STD-Besbes_x002d_Ouanes-2000" TOTAL_1="21" TOTAL_2="21" WEIGHT="10.606873840877714"/>
<CONT_DATA CI_END="0.35208398458319934" CI_START="-0.2499725787477608" EFFECT_SIZE="0.051055702917719284" ESTIMABLE="YES" MEAN_1="239.0" MEAN_2="236.0" ORDER="65" SD_1="64.0" SD_2="53.0" SE="0.153588680220633" STUDY_ID="STD-Innes-2002" TOTAL_1="81" TOTAL_2="89" WEIGHT="42.91073681307772"/>
<CONT_DATA CI_END="1.0247869724079208" CI_START="-0.8143441148609368" EFFECT_SIZE="0.10522142877349197" ESTIMABLE="YES" MEAN_1="58.9" MEAN_2="57.72" ORDER="66" SD_1="10.82" SD_2="10.58" SE="0.46917471488652057" STUDY_ID="STD-Reisner-1995" TOTAL_1="13" TOTAL_2="7" WEIGHT="4.598489417419496"/>
<CONT_DATA CI_END="0.48161462669828525" CI_START="-0.3077145413907224" EFFECT_SIZE="0.0869500426537814" ESTIMABLE="YES" MEAN_1="256.0" MEAN_2="248.0" ORDER="67" SD_1="87.0" SD_2="95.0" SE="0.2013631817510769" STUDY_ID="STD-Rudnitsky-1993" TOTAL_1="47" TOTAL_2="52" WEIGHT="24.96457971897642"/>
<CONT_DATA CI_END="0.9692910442877637" CI_START="0.010489276230326361" EFFECT_SIZE="0.489890160259045" ESTIMABLE="YES" MEAN_1="239.0" MEAN_2="202.0" ORDER="68" SD_1="83.0" SD_2="65.0" SE="0.24459678229302764" STUDY_ID="STD-Rudnitsky-1993a" TOTAL_1="35" TOTAL_2="34" WEIGHT="16.919320209648646"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.640177061883647" CI_END="0.5435730264003964" CI_START="0.047171328759238074" DF="4" EFFECT_SIZE="0.29537217757981726" ESTIMABLE="YES" I2="13.796392968327199" ID="CMP-002.01.02" NO="2" P_CHI2="0.3262482943727695" P_Z="0.019676445935263492" STUDIES="5" TAU2="0.0" TOTAL_1="128" TOTAL_2="129" WEIGHT="100.00000000000001" Z="2.33246112107418">
<NAME>FEV-1</NAME>
<CONT_DATA CI_END="0.7356404548736123" CI_START="-0.47548646509505377" EFFECT_SIZE="0.13007699488927926" ESTIMABLE="YES" MEAN_1="2.19" MEAN_2="2.07" ORDER="69" SD_1="0.89" SD_2="0.92" SE="0.30896662630586086" STUDY_ID="STD-Colacone-1990" TOTAL_1="21" TOTAL_2="21" WEIGHT="16.799145877413793"/>
<CONT_DATA CI_END="1.374312216084227" CI_START="0.057832234324264764" EFFECT_SIZE="0.7160722252042458" ESTIMABLE="YES" MEAN_1="2.35" MEAN_2="1.71" ORDER="70" SD_1="0.88" SD_2="0.87" SE="0.3358429012329278" STUDY_ID="STD-Lin-1993" TOTAL_1="19" TOTAL_2="19" WEIGHT="14.217983202900598"/>
<CONT_DATA CI_END="0.714186095629187" CI_START="-1.1290977950557786" EFFECT_SIZE="-0.2074558497132958" ESTIMABLE="YES" MEAN_1="47.71" MEAN_2="50.75" ORDER="71" SD_1="14.42" SD_2="13.23" SE="0.47023412297995104" STUDY_ID="STD-Reisner-1995" TOTAL_1="13" TOTAL_2="7" WEIGHT="7.252405205255388"/>
<CONT_DATA CI_END="0.9545600131404521" CI_START="0.06219057670210909" EFFECT_SIZE="0.5083752949212806" ESTIMABLE="YES" MEAN_1="1.66" MEAN_2="1.36" ORDER="72" SD_1="0.63" SD_2="0.54" SE="0.22764944750955612" STUDY_ID="STD-Shrestha-1996" TOTAL_1="38" TOTAL_2="42" WEIGHT="30.944049098349748"/>
<CONT_DATA CI_END="0.542961748583296" CI_START="-0.35168932411575565" EFFECT_SIZE="0.09563621223377017" ESTIMABLE="YES" MEAN_1="1.64" MEAN_2="1.57" ORDER="73" SD_1="0.77" SD_2="0.68" SE="0.2282315082715665" STUDY_ID="STD-Shrestha-1996a" TOTAL_1="37" TOTAL_2="40" WEIGHT="30.786416616080484"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.139031079837885" CI_END="0.506786508949322" CI_START="0.19634929558318948" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.3515679022662557" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.02" NO="2" P_CHI2="0.5201984747246409" P_Q="0.8108366459849057" P_Z="9.025608391982527E-6" Q="0.057286912124389744" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="325" TOTAL_2="332" UNITS="" WEIGHT="200.0" Z="4.43929011661031">
<NAME>2-3 hours</NAME>
<GROUP_LABEL_1>Continuous</GROUP_LABEL_1>
<GROUP_LABEL_2>Intermittent</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intermittent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours continuous</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.612853867618799" CI_END="0.5656527296581961" CI_START="0.1678581342265708" DF="4" EFFECT_SIZE="0.36675543194238347" ESTIMABLE="YES" I2="13.285785442302783" ID="CMP-002.02.01" NO="1" P_CHI2="0.3293750162184048" P_Z="3.014353370661904E-4" STUDIES="5" TAU2="0.0" TOTAL_1="197" TOTAL_2="203" WEIGHT="100.0" Z="3.6140633683649823">
<NAME>PEFR</NAME>
<CONT_DATA CI_END="0.6048580172391602" CI_START="-0.6048580172391602" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="52.0" MEAN_2="52.0" ORDER="74" SD_1="18.0" SD_2="14.0" SE="0.3086066999241838" STUDY_ID="STD-Besbes_x002d_Ouanes-2000" TOTAL_1="21" TOTAL_2="21" WEIGHT="10.813116508451749"/>
<CONT_DATA CI_END="0.8338552789091006" CI_START="0.22129591472376464" EFFECT_SIZE="0.5275755968164326" ESTIMABLE="YES" MEAN_1="274.0" MEAN_2="243.0" ORDER="75" SD_1="64.0" SD_2="53.0" SE="0.15626801538628415" STUDY_ID="STD-Innes-2002" TOTAL_1="81" TOTAL_2="89" WEIGHT="42.171727357070296"/>
<CONT_DATA CI_END="0.8992527794508915" CI_START="-0.9384878884850747" EFFECT_SIZE="-0.01961755451709163" ESTIMABLE="YES" MEAN_1="61.94" MEAN_2="62.16" ORDER="76" SD_1="10.82" SD_2="10.58" SE="0.4688200095593159" STUDY_ID="STD-Reisner-1995" TOTAL_1="13" TOTAL_2="7" WEIGHT="4.685428388566043"/>
<CONT_DATA CI_END="0.584911040514611" CI_START="-0.2058686239088187" EFFECT_SIZE="0.18952120830289612" ESTIMABLE="YES" MEAN_1="310.0" MEAN_2="291.0" ORDER="77" SD_1="100.0" SD_2="99.0" SE="0.2017332131255979" STUDY_ID="STD-Rudnitsky-1993" TOTAL_1="47" TOTAL_2="52" WEIGHT="25.305025055682837"/>
<CONT_DATA CI_END="1.0531489901039395" CI_START="0.08905558922100176" EFFECT_SIZE="0.5711022896624707" ESTIMABLE="YES" MEAN_1="296.0" MEAN_2="244.0" ORDER="78" SD_1="98.0" SD_2="81.0" SE="0.24594671343136493" STUDY_ID="STD-Rudnitsky-1993a" TOTAL_1="35" TOTAL_2="34" WEIGHT="17.024702690229077"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.468890300094695" CI_END="0.5761471175412809" CI_START="0.07967468879239442" DF="4" EFFECT_SIZE="0.3279109031668377" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.02" NO="2" P_CHI2="0.48262442351610024" P_Z="0.009624383314399581" STUDIES="5" TAU2="0.0" TOTAL_1="128" TOTAL_2="129" WEIGHT="100.0" Z="2.589040289566914">
<NAME>FEV-1</NAME>
<CONT_DATA CI_END="0.9428205765483008" CI_START="-0.2761312940035071" EFFECT_SIZE="0.3333446412723968" ESTIMABLE="YES" MEAN_1="2.53" MEAN_2="2.2" ORDER="79" SD_1="1.02" SD_2="0.92" SE="0.3109628238495056" STUDY_ID="STD-Colacone-1990" TOTAL_1="21" TOTAL_2="21" WEIGHT="16.58888338604278"/>
<CONT_DATA CI_END="1.3528194258796837" CI_START="0.0387930630920682" EFFECT_SIZE="0.695806244485876" ESTIMABLE="YES" MEAN_1="2.43" MEAN_2="1.79" ORDER="80" SD_1="0.87" SD_2="0.93" SE="0.3352169665239994" STUDY_ID="STD-Lin-1993" TOTAL_1="19" TOTAL_2="19" WEIGHT="14.275197113358162"/>
<CONT_DATA CI_END="0.6698294115870183" CI_START="-1.1761854658214443" EFFECT_SIZE="-0.2531780271172131" ESTIMABLE="YES" MEAN_1="50.19" MEAN_2="53.9" ORDER="81" SD_1="14.42" SD_2="13.23" SE="0.47093081606845644" STUDY_ID="STD-Reisner-1995" TOTAL_1="13" TOTAL_2="7" WEIGHT="7.233023514301852"/>
<CONT_DATA CI_END="0.8903533577262999" CI_START="0.0013666017937142283" EFFECT_SIZE="0.4458599797600071" ESTIMABLE="YES" MEAN_1="1.91" MEAN_2="1.62" ORDER="82" SD_1="0.68" SD_2="0.61" SE="0.22678650295229905" STUDY_ID="STD-Shrestha-1996" TOTAL_1="38" TOTAL_2="42" WEIGHT="31.18887348229712"/>
<CONT_DATA CI_END="0.6189741073070526" CI_START="-0.2768583348961259" EFFECT_SIZE="0.1710578862054634" ESTIMABLE="YES" MEAN_1="1.95" MEAN_2="1.81" ORDER="83" SD_1="0.88" SD_2="0.74" SE="0.22853288358086946" STUDY_ID="STD-Shrestha-1996a" TOTAL_1="37" TOTAL_2="40" WEIGHT="30.714022504000084"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.0490675598679056" CI_END="0.48443141051748556" CI_START="-0.4044324696862767" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.0399994704156044" ESTIMABLE="YES" I2="0.0" I2_Q="1.43563511869748" ID="CMP-002.03" NO="3" P_CHI2="0.5918313129340189" P_Q="0.3138118562454958" P_Z="0.8599801869688815" Q="1.0145654580174728" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="47" TOTAL_2="35" UNITS="" WEIGHT="200.0" Z="0.1763993861406276">
<NAME>4-6 hours</NAME>
<GROUP_LABEL_1>Continuous</GROUP_LABEL_1>
<GROUP_LABEL_2>Intermittent</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intermittent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours continuous</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.03450210185043277" CI_END="0.6708236655712938" CI_START="-0.3416654972039878" DF="1" EFFECT_SIZE="0.16457908418365302" ESTIMABLE="YES" I2="0.0" ID="CMP-002.03.01" NO="1" P_CHI2="0.852642901392759" P_Z="0.5240074075775736" STUDIES="2" TAU2="0.0" TOTAL_1="34" TOTAL_2="28" WEIGHT="100.0" Z="0.6371803066501338">
<NAME>PEFR</NAME>
<CONT_DATA CI_END="0.802688613364698" CI_START="-0.4102357831760188" EFFECT_SIZE="0.19622641509433963" ESTIMABLE="YES" MEAN_1="62.0" MEAN_2="58.0" ORDER="84" SD_1="20.0" SD_2="20.0" SE="0.30942517467364444" STUDY_ID="STD-Besbes_x002d_Ouanes-2000" TOTAL_1="21" TOTAL_2="21" WEIGHT="69.68082820443674"/>
<CONT_DATA CI_END="1.011239941190164" CI_START="-0.827548294348305" EFFECT_SIZE="0.09184582342092956" ESTIMABLE="YES" MEAN_1="67.26" MEAN_2="66.23" ORDER="85" SD_1="10.82" SD_2="10.58" SE="0.4690872511032335" STUDY_ID="STD-Reisner-1995" TOTAL_1="13" TOTAL_2="7" WEIGHT="30.319171795563268"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.549390447741015" CI_START="-1.3068772674178513" DF="0" EFFECT_SIZE="-0.3787434098384182" ESTIMABLE="YES" I2="0.0" ID="CMP-002.03.02" NO="2" P_CHI2="1.0" P_Z="0.4238254519587885" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="7" WEIGHT="100.0" Z="0.7998021369473229">
<NAME>FEV-1</NAME>
<CONT_DATA CI_END="0.5493904477410148" CI_START="-1.3068772674178513" EFFECT_SIZE="-0.3787434098384182" ESTIMABLE="YES" MEAN_1="53.6" MEAN_2="59.15" ORDER="86" SD_1="14.42" SD_2="13.23" SE="0.4735463839644169" STUDY_ID="STD-Reisner-1995" TOTAL_1="13" TOTAL_2="7" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2008-07-24 08:52:03 +0100" MODIFIED_BY="Toby J Lasserson">
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2008-07-24 08:51:55 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" REF_ID="CMP-001.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Absolute PEFR values (end of study)</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2008-07-24 08:52:03 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" REF_ID="CMP-001.02" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Absolute FEV1 values (end of study)</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>